Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Non-viral vectors for RNA delivery

Yi Yan¹, Xiao-Yu Liu¹, An Lu, Xiang-Yu Wang, Lin-Xia Jiang, Jian-Cheng Wang * 

Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.

ARTICLE INFO

Keywords:
RNA drugs
Non-viral vector
Biological barrier
Control release
Gene therapy

ABSTRACT

RNA-based therapy is a promising and potential strategy for disease treatment by introducing exogenous nucleic acids such as messenger RNA (mRNA), small interfering RNA (siRNA), microRNA (miRNA) or antisense oligonucleotides (ASO) to modulate gene expression in specific cells. It is exciting that mRNA encoding the spike protein of COVID-19 (coronavirus disease 2019) delivered by lipid nanoparticles (LNPs) exhibits the efficient protection of lungs infection against the virus. In this review, we introduce the biological barriers to RNA delivery in vivo and discuss recent advances in non-viral delivery systems, such as lipid-based nanoparticles, polymeric nanoparticles, N-acetylgalactosamine (GalNAc)-siRNA conjugate, and biomimetic nanovectors, which can protect RNAs against degradation by ribonucleases, accumulate in specific tissue, facilitate cell internalization, and allow for the controlled release of the encapsulated therapeutics.

1. Introduction

Among human disease treatment, traditional small molecule drugs and antibody drugs generally modulate disease pathology by targeting the downstream proteins of a gene-caused disease. Unfortunately, lots of pathogenic proteins cannot be targeted by current small molecule drugs and antibody drugs. In recent two decades, gene therapy, a more accurate and efficient treatment strategy, is currently emerging in clinic [1–3].

In 2018, the first therapeutic small interfering RNA (siRNA) (ONPATTRO™) was approved by United States Food and Drug Administration (FDA) [4]. A rapidly expanding market is being promising, as many emerging biopharmaceutical and biotech companies are developing RNA-based therapies. Several RNA-based products have successfully been approved for use in clinic, with many more in varying stages of the drug development pipeline [4–8]. The advent of RNA drugs has brought light to those diseases that has no drug treatment, including messenger RNA (mRNA), microRNA (miRNA), siRNA, antisense oligonucleotides (ASOs), RNA aptamers and so on. The scope of RNA application includes encoding disease-related proteins, silencing protein expression of specific genes, regulating protein function, mediating transcriptional activation of genes, etc.

However, unlike many small molecule and protein drugs, RNA molecules are negatively charged and sensitive to ubiquitous RNases, and their action sites are mostly intracellular. Therefore, the main difficulty in the development and application of RNA drugs lies in the delivery technology. The development of delivery systems will solve many problems existing in RNA delivery in vivo, which is the key for improving the efficacy of RNA drugs. It is now clear that mRNA encoding the spike protein of COVID-19 (coronavirus disease 2019) delivered by lipid nanoparticles (LNPs) exhibits the efficient protection of lungs infection against the virus [9,10]. Apart from LNPs, other non-viral nanocarriers such as lipid-based nanoparticles (NPs) [11,12], polymeric NPs [13,14], N-acetylgalactosamine (GalNAc)-siRNA conjugate [15] and biomimetic nanovectors [16], could also provide the nucleic acids with protection against degradation by nucleases, facilitate their uptake by cells and allow for the controlled release of the encapsulated therapeutic [14,17]. This review mainly focuses on the research progress of non-viral vectors for RNA delivery on the stage of pre-clinic, clinical trials and market. Currently available non-viral RNA delivery vectors generally include four categories: lipid-based NPs, polymeric NPs, inorganic NPs and biomimetic NPs [18–20]. However, many carriers on the stage of pre-clinic and clinical trials only stay at the levels of study due to the toxicity and effectiveness in vivo.
2. RNA drugs approved on the market

Since 1998 the first ASO drug Fomivirsen was marketed for the treatment of eye diseases (later withdrawn due to reduced clinical needs) [21], RNA drugs began to appear on the stage. In 2001, RNA interference (RNAi) technology was rated as one of the top ten scientific advances by *Science* magazine. However, due to the difficulty of delivering intact RNAs to tissue cells of interest, naked RNA drugs did not make much progress. With the development of chemical modification and delivery systems for nucleic acid, RNA drugs had been gradually gaining momentum. Since the first siRNA drug Patisiran was approved on the market in 2018 [22], RNA drugs have finally entered a stage of rapid development. At the end of 2019, the second siRNA drug Givosiran was approved [4,22,23]. More exciting, it is now clear that mRNA encoding the spike protein of COVID-19 delivered by LNPs exhibits the efficiency of protection from lungs infection by the virus [9,10,24]. The commercial potential and clinical value of RNA drugs have finally been proved after 20 years. At present, nine ASOs, four siRNAs, two mRNAs, and one aptamer drugs are on the market (Table 1), among which about 80% were launched after 2015, and most of the indications are genetic diseases. There are many other types of RNA drugs are in clinical trials (Table 2), including the relatively new miRNA mimic, antimiRNA, small activating RNAs (saRNA), etc. It is believed that more and more RNA drugs will achieve clinical translation in the next few years. Among the RNA drugs approved or clinical trial, the non-viral delivery strategies are a key step. LNPs and cationic delivery systems after systemic administration. After reaching the acidic endosomes of cells, ionizable lipids were ionized, which promotes endosomal escape and the release of encapsulated RNAs into cytoplasm, thus improved the RNA effects.

Now, three LNP-based RNA drugs have been approved on the market, including Alnylam’s Patisiran (ONPATTRO™), Pfizer’s BNT162b2 and Moderna’s mRNA-1273. Among them, the former is siRNA drug and the latter two are mRNA vaccines for COVID-19. The specific components of these formulations are shown in Table 3 and Fig. 1 [25,26]. Patisiran, as the first siRNA drug, was approved in 2018, which is the first clinical application of LNP and the first non-viral delivery system for gene drug delivery on the market. The launch of this drug marks the arrival of the era of nucleic acid nanomedicine.

During development, Alnylam found that the functional activity of the LNP/RNA system is strongly correlated with pKa of ionizable lipids used. The pKa value of ionizable amino head of lipids is 6.2–6.5, which displayed an ideal balance between biocompatible neutral charge during circulation to maintain stability and enough positive charge at acidic pH to ensure high encapsulation efficiency on RNAs. Among the reported ionizable lipids, dioleoyl-4-dimethylaminobutyrate (DLin-MC3-DMA, Patent NO. US8158601B2)-based LNP is one of the most effective siRNA delivery systems. The application of DLin-MC3-DMA greatly reduces the dose of siRNA, and at the same time increases the gene silencing efficiency of siRNA in liver tissues. In preparation of LNP, DLin-MC3-DMA is positively charged under acidic condition (pH < 7), while it is neutral at physiological value (pH = 7.4). In this way, the resulted LNP/RNA system is strongly correlated with pKa of ionizable lipids and further improve the RNA delivery efficiency. These ionizable lipids usually contain ionizable amino head groups with an acid dissociation constant (pKa) less than 7. Hence, ionizable amino heads of lipids are protonated and positively charged at pH < 6.0, which allow high encapsulation efficiencies on RNAs at acidic pH, while they are neutral at physiological condition (pH = 7.4). In this way, the resulted LNPs with neutral surface charge reduced toxicity associated with the positive charge and prolonged the circulation lifetime as compared with cationic delivery systems after systemic administration. After reaching the acidic endosomes of cells, ionizable lipids were ionized, which promoted endosomal escape and the release of encapsulated RNAs into cytoplasm, thus improved the RNA effects.

### Table 1
Marketed RNA products.

| Type | Product | Gene Target | Indication | Approval Year | Company |
|------|---------|-------------|------------|---------------|---------|
| ASO  | Vitrawene (Fomivirsen) | Cytomegalovirus gene (UL122) | Cytomegalovirus infection | 1998 | Ionis Pharmaceuticals |
|      | Kynamro (Mipomersen) | Apo-106 | Hypercholesterolemia | 2013 | Ionis Pharmaceuticals |
|      | Exondys 51 (Eteplisiren) | Dystrophin (exon 51) | Duchenne muscular dystrophy | 2016 | Sarepta Therapeutics |
|      | Spinraza (Nusinersen) | SMN2 | Spinal muscular atrophy | 2016 | Ionis Pharmaceuticals |
|      | Tegsedi (inotersen) | TTR | TTR-mediated amyloidosis | 2018 | Ionis Pharmaceuticals |
|      | Waylivra (Volanesorsen) | ApoCII Dystrophin (exon 53) | Familial chylomicronemia syndrome | 2019 | Ionis Pharmaceuticals/Akcea |
|      | Vynody 53 (Golirdisiren) | Dystrophin (exon 53) | Duchenne muscular dystrophy | 2019 | Sarepta Therapeutics |
|      | Vilepteo (silotarsiren) | Dystrophin (exon 53) | Duchenne muscular dystrophy | 2020 | Nippon Shinyaku |
|      | AMONDYS 45 (casimersen) | Dystrophin (exon 45) | Duchenne muscular dystrophy | 2021 | Sarepta Therapeutics |
|      | Onpatro (patisiran) | TTR | TTR-mediated amyloidosis | 2018 | Alnylam Pharmaceuticals |
| siRNA| Givlaari (givosiran) | ALAS1 | Acute hepatic porphyrias | 2019 | Alnylam Pharmaceuticals |
|      | OXLUMO (lumasiran) | Glycolate oxidase | Primary hyperoxaluria type 1 | 2020 | Alnylam Pharmaceuticals |
|      | Inclisiran (Leqplio) | PCSK9 | Hypercholesterolemia | 2020 | Novartis/ Alnylam Pharmaceuticals |
| Aptamer | Macugen (Pegaptanib) | VEGF-165 | Age-related macular degeneration and diabetic macular edema | 2004 | Eyetech Pfizer |
| mRNA | Comirnaty (tozinamab) | SARS-CoV-2 spike protein mRNA | COVID-19 | 2020 | BioNTech/Pfizer |
|      | mRNA-1273 | SARS-CoV-2 spike protein mRNA | COVID-19 | 2020 | Moderna/NIAID/BARDA |

Abbreviation: Apo: Apolipoprotein; SMN2: Survival of motor neuron 2; TTR: Transthyretin; ALAS1: Aminolevulinate synthase 1; PCSK9: Proprotein convertase subtilisin/kexin type 9; VEGF: Vascular endothelial growth factor; COVID-19: Coronavirus disease 2019.
| Drug | Target | Vector | Conditions | Stage | Date | NCT Number |
|------|--------|--------|------------|-------|------|------------|
| siRNA Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA | KrasG12D | Exosome | KRAS NP_004976.2:p.G12D Metastatic Pancreatic Adenocarcinoma | Phase 1 | January 27, 2021- March 31, 2022 | NCT03608631 |
| | | | Pancreatic Ductal Adenocarcinoma Stage IV Pancreatic Cancer A/JCC v8 | | | |
| BMS-986263 | HSP47 | LNP | NASH | Phase 2 | March 17, 2021- January 9, 2024 | NCT04267393 |
| NBF-006 | GSTP | LNP | NSCLC; Colorectal Cancer; | Phase 1 | March 18, 2019- March 2023 | NCT03819387 |
| siG12D-LODER | KRAS | Polymer | KRAS G12D siRNA derived Exosomes with Apo(a) enriched by miR-124 | Phase 2 | March 7, 2018-August 2023 | NCT01676259 |
| STP705 | TGF-β1 | LNP | LOX-1 | Phase 1 | April 29, 2021-April 29, 2021 | NCT04844840 |
| ALN-AGT01 | AGT | GaINAc conjugated | Hypertension | Phase 2 | June 25, 2021- December 2024 | NCT04936035 |
| ALN-VSP02 | KSP | SNALP | Solid Tumors | Phase 1 | July 2010-September 2012 | NCT01158079 |
| Ato027 | PKN3 | Cationic lipoplex | Carcinoma, Pancreatic Ductal | Phase 1/2 | March 2013-January 2016 | NCT01808638 |
| mRNA BI 1361849 | NY-ESO-1 | MAGE-C2 Survivin 5 T4 MUC1 Membrane-anchored prefusion-stabilized spike protein of SARS-CoV-2 | Cationic protein prostatine | Metastatic NSCLC; NSCLC | Phase 1/2 | December 20, 2017- December 2024 | NCT03164772 |
| BNT162b2 | MAGE-C1 Survivin 5 T4 MUC1 Membrane-anchored prefusion-stabilized spike protein of SARS-CoV-2 | LNP | SARS-CoV-2 Infection, COVID-19 | Phase 2/3 | March 24, 2021- September 27, 2023 | NCT04816643 |
| mRNA-2416 | OX40L | LNP | Relapsed/Refractory Solid Tumor | Relapsed/Refractory Solid Tumor | Phase 1/2 | August 9, 2017- September 20, 2022 | NCT03323398 |
| BNT113 | HPV16+ | Liposome | Cancer; Metastatic Head and Neck Cancer | Metastatic Head and Neck Cancer | Phase 2 | January 7, 2021-May 2025 | NCT04534205 |
| BNT112 | RBL038 RBL039 RBL-040 RBL-041 RBL-045 | LPX | Prostate Cancer | Prostate Cancer | Phase 1/2 | December 19, 2019- July 2023 | NCT04382898 |
| pp65-shLAMP DC with GM-CSF | pp65 | DCs | Glioblastoma Multiforme; Glioblastoma; Malignant Glioma; Astrocytoma, Grade IV; GBM | Glioblastoma Multiforme; Glioblastoma; Malignant Glioma; Astrocytoma, Grade IV; GBM | Phase 2 | August 2016-June 2024 | NCT03291002 |
| CV7202 | RABV-G | LNP | Rabies | Rabies | Phase 1 | October 12, 2018- January 2023 | NCT03713086 |
| SARS-CoV-2 mRNA Vaccine | RBD of the SARS-CoV-2 spike protein | LNP | COVID-19; SARS-CoV-2 | COVID-19; SARS-CoV-2 | Phase 3 | May 28, 2021-May 30, 2023 | NCT04847102 |
| mRNA-4157 | 34 neoantigens | LNP | Melanoma | Melanoma | Phase 2 | July 18, 2019-June 30, 2024 | NCT03897881 |
| miRNA Remlarsen (MRG-201) | miR-29 | cholesterol-conjugated | Keloid | Keloid | Phase 2 | June 11, 2018-June 24, 2020 | NCT03601052 |
| TargomiRs | miR-16 mimic | EDVs | Malignant Pleural Mesothelioma; NSCLC | Malignant Pleural Mesothelioma; NSCLC | Phase 1 | 2014-January 4, 2017 | NCT02369198 |
| MRX34 | miR-34 | LNP | Primary Liver Cancer; SCLC; Lymphoma; Melanoma; Multiple Myeloma; Renal Cell Carcinoma; NSCLC | Primary Liver Cancer; SCLC; Lymphoma; Melanoma; Multiple Myeloma; Renal Cell Carcinoma; NSCLC | Phase 1 | April 2013-May 2017 | NCT02862145 |
| allologenic mesenchymal stem cells derived exosome enriched by miR-124 | miR-124 | Exosome | Cerebrovascular Disorders | Cerebrovascular Disorders | Phase 1/2 | April 17, 2019-December 17, 2021 | NCT03384433 |
| INT-183 | miR-193a-3p | LNP | Solid Tumor | Solid Tumor | Phase 1 | December 18, 2020-December 2024 | NCT04675996 |
| ASO Pelacarsen (TQJ230) | Apo(a) | GalNAc conjugated | Cardiovascular Disease and Lipoprotein(a) | Cardiovascular Disease and Lipoprotein(a) | Phase 3 | December 12, 2019-June 27, 2024 | NCT04023552 |
| AKCAE-APOCIII-LRx | ApoC-III | GalNAc conjugated | Familial Chylomicronemia Syndrome | Familial Chylomicronemia Syndrome | Phase 3 | November 18, 2020-June 2023 | NCT04568434 |
| IONIS-FB-LRx | Factor B | GalNAc conjugated | Primary IgA Nephropathy | Primary IgA Nephropathy | Phase 2 | December 4, 2019-December 2023 | NCT04014335 |
| GVI007 | PCSK9 | Locked nucleic acid (LNA) | Hypercholesterolemia | Hypercholesterolemia | Phase 1 | February 7, 2018-August 18, 2020 | NCT03427710 |

(continued on next page)
sn-glycero-3-phosphocholine (DSPC) can further increase the stability of LNP [27]. Also, the introduction of PEGylated lipids can increase the storage stability by avoiding particle aggregation. Although the PEGylated nanoparticles can indirectly affect the interaction of LNP with cell surface, the PEG lipid (PEG-C14) containing short acyl chains used in Patisiran can gradually dissociate from the LNP [28, 29] during blood circulation. After intravenous administration, Patisiran is adsorbed on endogenous Apolipoprotein E (ApoE) [29]; the removal of surface PEG layer can enhance the binding of ApoE to the surface of LNP. After accumulating in the targeted liver tissues, the uptake of LNP is mediated by ApoE receptors (such as low-density lipoprotein receptors) on the surface of hepatocytes [29]. After entering hepatocytes, the DLin-MC3-DMA is protonated at low pH value in the endosomes, and further interacts with negatively charged endogenous lipids, resulting in instability of endosomal membrane and realizing the release of loaded siRNA [29]. For Patisiran, the siRNA released to the cytoplasm can silence the expression of hereditary transthyretin amyloidosis (hATTR) mRNA by forming the RNA-induced silencing complex (RISC), reducing the production of misfolded TTR protein [30].

The primary adverse effect of Patisiran was mild-to-moderate...
infusion-related reactions, the incidence of which could decrease over time. In the phase 3 trial, approximately 20% of the patients (225 people in total) receiving Patisiran had mild or moderate infusion-related reactions, while for those who received placebo the rate was 10%; the overall incidence and types of adverse reactions were similar [31,32].

2.2. GalNAc-conjugated siRNA

Among the RNA drugs currently approved on the market, three of them use GalNAc coupling technology for siRNA delivery. Givosiran (Aplylam), Lumasiran (Aplynam) and Inclisiran (Novartis) have significant advantages in the treatment of liver-related diseases. The GalNAc-conjugated RNA drugs on the market and in clinical trials are listed in Table 4.

GalNAc is a high-affinity targeting ligand of Asialoglycoprotein receptor (ASGPR) [33]. ASGPR is specifically highly expressed on the surface of hepatocytes – approximately 10⁶ per hepatocytes [34], while the expression of other receptors on cell surface is only 10⁴–10⁶ or even lower. The selection of ASGPR receptor underwent the selection of sugar molecule type, number of antennae, spatial distance and other factors. The triantennary GalNAc was optimized and used as a specific ligand targeting to ASGPR with high affinity. In addition to the advantages of quantity, ASGPR is also an extremely efficient endocytic-circulating receptor with a circulation rate of about 15 min [34], while the circulation time of other cell surface recyclable receptors is usually 90 min. In summary, the two characteristics of the large number of receptors and short circulation time determine that GalNAc-siRNA conjugates can achieve efficient cell internalization.

When GalNAc binds to ASGPR, it can enter the endosome through clathrin-mediated endocytosis. After entering early endosomes, ASGPR dissociates from GalNAc-siRNA conjugate at low pH and circulates back to the surface of hepatocytes. As the early endosomes acidify and mature, they transform into late endosomes or multivesicular body (MVBs). It is estimated that only <0.01% of siRNA can escape from late endosomes or MVBs to the cytoplasm [35]. However, the high-efficiency uptake mentioned above allows nearly one million siRNA to enter the early endosomes every 15 min. Therefore, the amount of siRNA reaching the cytoplasm far exceeds the threshold of RNAi response, which can well meet the dosing needs, making short-term drug efficacy possible. As for the siRNA molecules retained in acidic compartments, it is essential for the maintenance of long-term efficacy. Studies have shown that long-term effect of GalNAc-siRNA conjugates is due to the enhanced metabolic stability of siRNA after chemical modification, which can achieve greatly improvement of siRNA survival rate in acidic compartment and form intracellular siRNA reservoirs [36]. These retained siRNA can be slowly released from acidic compartments to the cytoplasm, and then loaded into the RISC, extending the pharmacodynamic durability of GalNAc–siRNA conjugates.

Although both LNP and GalNAc have excellent accumulation and uptake in the liver, the delivery strategy based on GalNAc is more advantageous than LNP. First of all, LNP intravenous injection can cause infusion-related reactions, so it needs to be used in combination with antihistamine, acetaminophen and dexamethasone; while GalNAc-conjugated nucleic acid drugs can be administered subcutaneously and avoid the safety problems caused by the immunogenicity of lipid molecules and PEG when using LNP. In addition, GalNAc-based products are easier to scale up than LNP-based products, and they are also superior in terms of dosage and frequency of administration. Currently, a large number of RNA drugs in clinical trials are based on GalNAc technology.

3. Synthetic non-viral vectors for RNA delivery

3.1. Challenges and strategies

Actually, RNAs are always subjected to both systemic and cellular barriers that hinder their access to intracellular targets. Firstly, RNAs are highly susceptible to the destruction by nucleases or hydrolases in blood or body fluids, and rapid clearance by the kidney. As reported, unprotected RNAs have an extremely short metabolic or systemic half-life (e. g., less than 7 min) [37]. Secondly, RNAs with the physicochemical properties of hydrophilic, negatively charged and high molecular weight

Table 4
GalNAc-conjugated RNA drugs.

| On the market | In clinical trials |
|---------------|--------------------|
| **RNA type**  | **Product**         | **Target** | **Indications** | **Company** | **Study start year** |
| siRNA         | Givlaari (givosiran)| ALAS1      | Acute hepatic porphyrias | Aplynam Pharmaceuticals | 2019 |
| siRNA         | OXLUMO (lumasiran)  | Glycolate oxidase | Primary hyperoxaluria type 1 | Aplynam Pharmaceuticals | 2020 |
| siRNA         | Inclisiran (Leqvio) | PCSK9      | Hypercholesterolemia | Novartis/Aplynam Pharmaceuticals | 2020 |

| RNA type | Drug | Target | Conditions | Phase | Identifier | Start-Complete |
|----------|------|--------|------------|-------|------------|---------------|
| siRNA    | SLN124| TMPRSS6| Non-transfusion-dependent Thalassemia, Low Risk | I     | NCT04176653 | August 20, 2019-October 14, 2021 |
| siRNA    | Lumasiran (ALN-GO1) | HAO1 | Primary Hyperoxaluria Type 1 | II    | NCT03505451 | April 4, 2018-June 2023 |
| siRNA    | ALN-PCSS | PCSK9 | Homozygous Familial Hypercholesterolemia | II    | NCT02963311 | December 13, 2016-October 8, 2018 |
| siRNA    | ALNAT3SC (Fitusiran, SAR439774) | AT | Hemophilia A; Hemophilia B | I/II  | NCT02554773 | September 18, 2015-August 2023 |
| siRNA    | ALN-AGT01 | AGT | Hypertension | II    | NCT04936035 | June 25, 2021-December 2024 |
| ASO      | Pelacarsen (TQJ230) | Apo(a) | Cardiovascular Disease and Lipoprotein(a) | III   | NCT04023552 | December 12, 2019-June 27, 2024 |
| ASO      | IONIS-FB-LRx | Factor B | Primary IgA Nephropathy | II    | NCT03313778 | December 4, 2019-December 2023 |
| ASO      | ApoC-III | Familial Chylomicronemia Syndrome | III   | NCT04568434 | November 18, 2020-June 2023 |

All the information from https://clinicaltrials.gov/.
Abbreviation: TMPRSS6: transmembrane serine protease 6, HAO1: hydroxyacid oxidase 1, AT: antithrombin.
is difficult to cross cell membrane into cytoplasm. Thirdly, after cell internalization, internalized RNAs were often trafficked through early/late endosomes and acidic lysosomes microenvironment and destroyed by enzyme degradation, which limits integral RNAs to exert gene effects (Fig. 2). Therefore, for efficient delivery of RNAs, especially systemic delivery, one of the most attractive approaches is the development of non-viral vectors to overcome the above hurdles. The ideal delivery system for RNAs should: 1) have efficient encapsulation and protection on RNAs from nuclease-based degradation during systemic delivery; 2) prolong blood circulation time, prevent rapid clearance by kidney and phagocytosis by liver or spleen; 3) enhance targeted tissue/organ penetration and accumulation; 4) facilitate targeted cell internalization; 5) avoid lysosomal degradation during intracellular trafficking pathway; 6) enhance release of RNAs during intracellular trafficking pathway.

So far, to overcome the limitations of in vivo RNA drugs application, many synthetic non-viral vectors and biomimetic vectors have been employed for RNA delivery. In the following sections, different approaches in the preclinical studies or clinical trials in terms of each significant hurdle for safe and efficient delivery of RNAs are discussed. Synthetic non-viral vectors are constructed by designing many types of natural or synthetic materials and formulations for delivering RNAs, including lipid-based NPs, polymer-based NPs, inorganic NPs, nucleic acid-based nanostructures and others.

Fig. 2. Extracellular and intracellular barriers for in vivo delivery of RNAs using non-viral vectors. (a) protection of RNAs from nuclease-based degradation; (b) prolong circulation of RNA-loaded nanocarriers by avoiding phagocytosis by mononuclear phagocytic system and rapid kidney clearance; (c) enhance tissue/organ-selective accumulation of RNAs; (d) enhance cellular internalization; (e) avoid intracellular lysosomal degradation; (f) enhance intracellular release of RNAs.
3.2. Protection of RNAs from nuclease-based degradation

Due to the instability and negatively charged characters of RNAs, different delivery systems have been widely developed to achieve efficient encapsulation and protection from degradation by RNase. Among the NPs formulation, different structure of materials, method of preparation, and incorporation of excipients can greatly affect the protection efficiency and therapeutic outcome. The strategies for encapsulation of RNAs can be classified into several types: electrostatic adsorption to the surface of pre-formed NPs, incorporation into the core of NPs (core-shell encapsulation), electrostatic interaction-based “layer-by-layer” approach, and non-electrostatic interaction-based encapsulation. Examples of NPs and strategies for RNAs loading are briefly summarized in Table 5.

3.2.1. Protection by electrostatic adsorption

The most common strategy was simply electrostatic adsorption of RNAs onto the surface of pre-formed cationic NPs or combination RNAs with cationic components of NPs to form lipoplexes or polyplexes. This relatively facile manner. Cationic lipids like DOTAP, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), et al. are always used as the major component combining with other helper lipids (DOPC, DOPE, DSPC and cholesterol) to self-assemble into cationic liposomes with bilayer membrane via hydrophobic interactions, and thereby facilitating RNAs adsorption (named lipoplexes) (Fig. 3A).

Cationic polymeric materials such as PEI, PLL, poly-arginine or PAMAM dendrimers, can usually form polyplexes upon complexation with RNAs (Fig. 3B). As reported, branched PEI with molecular weight of 25 kDa could complex with siRNA above the N/P ratio of 2.5 [92]. PAMAM dendrimers composed of the triethanolamine core and branching units starting 10 successive bonds from the center amine were referred to as Gn (n: dendrimer generation number). From generation 1 to 7, the corresponding dendrimers G1–G7 have 6, 12, 24, 48, 96, 192, and 384 terminal amine groups, respectively [93]. PAMAM dendrimers G7 were able to completely entrapsiRNA at N/P ratios >2.5 [45]. Besides, to further improve the biostability of polyelectrolyte complexes, A–B-type block copolymer with PEG (A block) and polycations (B block) had been widely used in the construction of RNA nanocarriers (Fig. 3C), like PLL-PEG, PEI-PEG et al. Another strategy to improve the biostability and encapsulation efficiency of polycations/RNAs complexes is to construct amphiphatic-based polymer systems via introducing the hydrophobic moieties (Fig. 3D) such as PLA, PLGA or PCL and so on. For example, amphiphilic PAMAM dendrimers G5 bearing hydrophobic alkyl chain was able to form stable self-assembled complexes with siRNA and completely retard the migration of siRNA in a gel at N/P ratios over 2.5, while dendrimer G5 devoid of the alkyl chain could not completely retard siRNA migration even at the N/P ratio of 10 [46].

However, these polymeric vectors also exhibited limited encapsulation efficiency, positive charge-associated cytotoxicity, and inevitably interfered by negatively charged biomacromolecules under biological conditions, which were of limited interest for clinical application. To ameliorate these drawbacks, the combination of the above two strategies is proposed by integrating hydrophobic block (C) randomly into the polycationic segments to construct A-(B/C)-type copolymer or by introducing hydrophobic block (C) to construct A–B–C and A–C–B types of triblock copolymers. Thus, these obtained polymeric vectors had better self-assembling capability and protection ability with the help of hydrophobic interaction and electrostatic interaction. Dong et al. [94] focused on the effect of distribution of hydrophobic segments in the chains of amphiphilic cationic polymers on siRNA delivery. In this study, PEG–PAM–PDP (E–A–D), PEG–PDP–PAM (E–D–A) and PE–P(AM/DP) (E–A/D) were self-assembled into micelles for siRNA delivery (Fig. 4A), among which aminoethyl methacrylate (AM) was used as the cationic moieties to bind siRNA, and 2-(dipropylamino)ethyl methacrylate (DP) was used as the pH-sensitive hydrophobic core moieties. The results showed that M_{E,A,D} could completely bind siRNA at N/P = 2, but N/P = 5 was needed for M_{E,D,A} or M_{E,M,D} besides, M_{E,A,D}/siRNA and M_{E,D,A}/siRNA had better stability in size with time than that of M_{E,M,D}/siRNA micelles. Thus, the distribution of hydrophobic moieties in the polymer chains might affect the RNA binding and the stability of the formed NPs.

In addition to the micelles formed by triblock copolymers, polymeric hybrid micelles (PHMs) consisting of different amphiphilic diblock copolymers were also constructed for RNAs adsorption encapsulation. Simply adjusting the ratio of the two-diblock copolymers instead of altering the copolymer architecture allows easy regulations of the proportion of cationic segments or hydrophobic segments in PHMs. For instance, PHMs with different ratios of PCL-PEG and PCL-PEI were constructed for miRNA delivery. By adjusting the ratio of PCL-PEI to achieve efficient condense of miRNA at an N/P ratio of 8/1, the PHMs avoided the need for extensively and time-consuming resynthesis of copolymer materials to adjust the properties of polymeric nanocarriers [94].

However, electrostatic adsorption-based RNA nanocarriers are generally susceptible to cause leakage of RNAs induced by replacement of anionic substances in the blood or form polyelectrolyte aggregates with biomacromolecules under biological conditions, and easy to induce excessive charge-associated cytotoxicity and non-specific interactions with serum or plasma proteins.

3.2.2. Protection by electrostatic interaction-based layer-by-layer encapsulation

Given the disadvantage of surface adsorption-based RNA delivery systems, the alternative protection strategy of RNAs is Layer-by-Layer (LbL)-based nanocarriers, which can encapsulate RNAs into the multi-layered NPs by sequential electrostatic interaction. This strategy has facile preparation by simple adsorption and multiple alternate layers to increase RNA loading to the NPs, while also expand the variety of NP types (like polymer-lipid hybrid NPs, or inorganic-organic hybrid NPs) and functionality of different layers. The stable core of NPs and material choice for each layer are essential to ensure layer attachment for each step. For instance, this method had been successfully used to attach siRNA to PLGA NPs surrounded by layers of alternating polyelectrolyte nanolayers. poly-L-arginine (poly-L-Arg) was layered onto the negatively charged PLGA NPs substrate first to create a positively charged surface. siRNA molecules were then layered onto the poly-L-Arg layers as a negative polyelectrolyte layer, onto which an additional poly-L-Arg layer was added. Finally, HA, a negatively charged natural polysaccharide, was deposited as an outer layer. Moreover, anti-CD20 antibodies (CD20-Ab), which specifically bind with the lymphoma-specific receptor protein CD20, were chemically conjugated on the outer HA layer of the LbL-NPs (Fig. 4B). Cryo-TEM images clearly displayed the uniform nanolayer coating on the spherical PLGA NPs core. In addition, gold NPs (AuNPs) also can be used as the core for LbL coated approach by depositing the 11-mercaptoundecanonic acid (MUA) on the surface of Au NPs surface Thereafter, the NPs were consecutively added to oppositely charged PEI25 kDa and siRNA. It was calculated to be around 780 siRNA molecules per PEI/siRNA/PEI-AuNP [77]. Paula T et al. [70] developed a single NP platform through the modular and controlled layer-by-layer process to co-deliver siRNA and a chemotherapy drug. The uniformly-sized, negatively charged carboxyl-modified polysacrylate latex NPs (CML) were used as a model NP core. Several polycations were screened for the construction of siRNA LbL, thin films, such as poly-peptides, PEI, CS and PBAE, and poly-L-Arg were identified as the promising candidates for in vivo applications due to their high siRNA loading efficiency, film stability and low cytotoxicity. The LbL film of poly-L-Arg was able to load approximately 3500 siRNA molecules per NP per layer, implying a conformal coating of siRNA on the NP with greater than 95% surface coverage. In comparison, this loading was substantially greater than the PEI/siRNA LbL NPs with approximately 500 siRNA molecules per layer. Besides, a lower N/P ratio in the poly-L-Arg/siRNA LbL NPs was found to be 1.7, which led to less toxic effects.
| Method of Incorporation | Type of RNA | Nanocarriers components | Encapsulation efficiency | Reference |
|-------------------------|-------------|--------------------------|--------------------------|-----------|
| Electrostatic Adsorption | siRNA       | Branched PEI 25 kDa      | Complexed with siRNA above the N/P ratio of 2.5 | [38]      |
|                        | siRNA       | Linear PEI               | N/P ratio of 5            | [39]      |
|                        | siRNA       | BPAE-SS                  | ~100% at polymer/siRNA weight ratios higher than 10 | [40]      |
|                        | siRNA       | ABP                      | ~95% condensation of siRNA at ABP/siRNA weight ratios of greater than 1.5 | [41]      |
|                        | siRNA       | PLGA-PEI                 | Encapsulation efficiency of ≥ 1%, loading siRNA of 198 ± 5 μg/30 μg | [42]      |
|                        | siRNA       | CS, γ-PGA                | CS/siRNA complexes at N/P ratios ranging from 50/1 to 200/1; CS/siRNA/γ-PGA complexes at N/P/C ratio ranging from 100/1/50 to 1/100/1/50 | [43]      |
| Core-shell encapsulation | miRNA      | PCL-PEI, PCL-PFG          | Efficiently condense miRNA at an N/P ratio of 8:1 | [44]      |
|                        | siRNA       | PAMAM dendrimers G7 (Gn: dendrimer generation number)) | Completely entrap siRNA at N/P ratios > 2.5 | [45]      |
|                        | siRNA       | Amphiphilic PAMAM dendrimers G5 bearing different alkyl chain length and dendron size | Only the combined effect of the hydrophobic alkyl chain and the cationic hydrophilic PAMAM dendron was able to complexed with siRNA completely at N/P ratios over 2.5 | [46]      |
|                        | siRNA       | PCL-g-PDMAEMA, PGA-g-mPEG (or PGA-g-PAG:folate) PAMAM-PG-PLL | Totally encapsulated even at N/P – 3.1 | [47]      |
|                        | siRNA       | Cationic lipid DC-6-14, cholesterol, dioleylphosphatidylethanolamine, vitamin A | Complexed completely with siRNA at the N/P ratio of 1 and above | [48]      |
|                        | siRNA       | Cationic lipid RPR209120 (2-[3-(3-amino-propyl)-amino]-propylamino)-N-diteradecylicarboxamyl-thyl-acetamide, 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE), | Entrapment efficiencies were 95.6 ± 3.0% | [49]      |
|                        | siRNA       | DOTAP                   | The DOTAP siRNA ratio was 2:1 (vol/wt), encapsulation efficiency of 89.4% | [50,52]   |
|                        | miRNA       | mPEG-PLGA-PLL            | siRNA was completely loaded into the polymeromes at siRNA/polymer ratio of 80/100 (w/w) (N/P ratio of 0.45) | [53]      |
|                        | siRNA       | PEG-PTMC-DTC-PEI, cNGQ-PEG-PTMC-DTC | Complete siRNA binding at N/P ratio of 3:1 | [54]      |
|                        | miRNA       | G4 PAMAM, humanized Archaeoglobus ferritin (HumFt) | One nanocapsule with single siRNA inside | [55]      |
|                        | siRNA       | Acrylate guanidine, N’N’-bis(acryloyl) cystamine containing disulfide bonds, polyethylene glycol with acylate and succinate functional end groups, Angiopep-2 (Arg) peptide PCL-PEI, DOPE, cholesterol, DSPE-PFG | Encapsulation efficiency >98% at N/P – 5 | [56]      |
|                        | siRNA       | Cationic lipid-like compound (PEI-C12), PLGA, lecithin, DSPE-PEG, peptide H2K(R2)3 | Entrapment efficiency of 87.1 ± 1.79%, drug loading was 322.96 ± 6.66 pmol of siRNA per mg of H2K(R2)3-PSNPs | [57]      |
|                        | siRNA       | mPEG08-PLA25K, BHEM-Chol | Encapsulation efficiency of siRNA could be above 90% and the siRNA loading weight ratio was up to 4.47% | [58]      |
|                        | siRNA       | Lanthanum phosphate, CS | Efficient encapsulation of siRNAs in CS/LaP/ siRNA NPs and protection from enzymatic degradation in intestinal fluid up to 72 h | [59]      |
|                        | siRNA       | Bioreducible cholesterol-grafted poly(amideamine) (pPAA-Chol polymer), DOTAP, DOPE, cholesterol, DSPE-PEG (or DSPE-PEG-T7) | One nanocapsule with single siRNA inside | [60]      |
|                        | miRNA       | PBAE polymer, EDOPC, DOPE, DSPE-PEG2000 | miRNA was fully encapsulated at PBAE/ siRNA ratio (w/w) of 20 or beyond | [61]      |
|                        | siRNA       | PLGA, lecithin, cationic lipid G0-C14, DSPE-PG0x | siRNA encapsulation efficiency at ~80% and a loading of ~640 pmol siRNA/mg PLGA | [62]      |
|                        | siRNA       | Cationic compound SW-01, ionizable lipid, DOPE, PEG-lipid Mesoporous silica nanoparticles (MSN), DOTAP, block copolymer 454 | Encapsulation efficiency of ~100% remained consistent over a 6-week duration | [63]      |
|                        | siRNA       | PEG77-XPLG*LAGxX-PCL17, Fe3O4 NPs, FITC-SiO2, PEI-FA | Complete siRNA binding at N/P ratio of 3:1 | [64]      |
|                        | shRNA       | Au NPs, CS               | Complete complexed with shRNA at N/Ps/ shRNA weight ratio of 15:1 | [65]      |
|                        | siRNA       | Au NPs, thiolated LPEI, PEGylated LPEI | Total siRNA loading at N/P 2 and above | [66]      |
|                        | shRNA       | carboxyl-modified polystyrene latex NPs (CML), poly-L-Arg | A single bilayer on the NP surface could load up to 3500 siRNAs | [67]      |
|                        | shRNA       | Dextran sulfate, poly-L-arginine, CaCO3 | siRNA loading efficiency at 95% | [68]      |
|                        | shRNA       | DOTAP, HA, CMO, HAase | Complete loading at (Au-PEI/CS-Aco/PEI)/ shRNA mass ratio of 5:1 | [69]      |
|                        | siRNA       | PLGA, poly-L-Arg, HA-methyltetrazine conjugate, CD20 antibody | – | [70]      |

(continued on next page)
Table 5 (continued)

| Method of Incorporation | Type of RNA | Nanocarriers components | Encapsulation efficiency | Reference |
|------------------------|-------------|--------------------------|--------------------------|-----------|
| siRNA                  | Au NPs, PEI, polymer SS37, polymer 447 | Encapsulation efficiency of 94%–100%, layering efficiencies of 80 ± 3% | [75] |
| siRNA                  | Au NPs, PLL | Total 4 layers of PLL and 3 layers of siRNA | [76] |
| siRNA                  | Au NPs, 11-mercaptooundecanoic acid (MUA), PEI 25 kDa | Around 780 siRNA molecules per PEI/siRNA/PEI-AuNP | [77] |
| miRNA                  | PLGA, PLL | Loading efficiency of 99%, such that 0.25 mg of PLGA NPs contained 10 amoles miRNA | [78] |
| miRNA                  | mesoporous titania NPs (MTN@), PLL, silica, PEG-block-poly- (l-aspartic acid) (PEG-b-PLL), paclitaxel (PTX) | miR708 was efficiently loaded at an N/P ratio of 2:1 | [79] |
| siRNA                  | CPG-g-PCL, siSTAT3 linker | The ratio of tailed-TET to siRNA linker at 1:1.8 | [80] |
| siRNA                  | DNA tetrahedron with tails (tailed-TET) | The ratio of tailed-TET to siRNA linker at 1:1.8 | [80] |

Non-electrostatic interaction-based encapsulation

| siRNA                  | DOX-HC, PEG-b-PLA | Hydrophobic [siRNA&DOX] with an encapsulation efficiency of 41.16 ± 0.47% | [82] |
| siRNA                  | Zinc(II)-bis(dipicolylamine) (ZnBDPA) lipid derivatives with different fatty acids, GMO, pluronic F108 | Nearly 100% loading efficiency of siRNAs | [80] |
| siRNA                  | DOPG, DOPE, calcium ions | The ratio of tailed-TET to siRNA linker at 1:1.8 | [80] |
| siRNA                  | Calcium phosphate, AHA | The molar ratio of GOA/miR at 120:1 | [86] |
| siRNA                  | GOA prodrugs | The incorporation efficacy of siRNA was about 94% at the PEG-PB to siRNA weight ratio of 20 | [88] |
| siRNA                  | Amphiphilic HA conjugate bearing 5i-cholic acids and Zn2+-dipicolylamine complexes (Zn-DPA) | The incorporation efficiency of siRNA was about 94% | [88] |
| siRNA                  | PEG-b-poly(β-hydroxybutyrate) (PEG-β-PHO), calcium phosphate | The incorporation efficiency of siRNA was about 94% | [88] |
| siRNA                  | HA | The siRNA loading capacity per MSN particle was estimated to be ~1.25 pmol/μg | [89] |
| siRNA                  | Mesoporous silica NPs (MSN), calcium ion | Unmodified and peptide-conjugated single-stranded oligonucleotides (including 122S, 122S, ASI+ and N-G3139) could be effectively encapsulated at a base ratio of 5:1 (~80%) | [91] |

| AS1411 or single-stranded RNAs (122S) or antisense oligonucleotide (G3139) | Nucleobase-lipid DDBAs (DOTA, DNTA, DOCA or DNA) | The siRNA loading capacity per MSN particle was estimated to be ~1.25 pmol/μg | [90] |

Abbreviation: SS37: 1-(3-aminopropyl)-4-methylpiperazine end-modified poly(N,N’-bis(acryloyl)cysteamine-co-3-amino-1-propanol), 447: 1-(3-aminopropyl)-4-methylpiperazine end-modified poly(1,4-butanedioyl diacrylate-co-4-amino-1-butanol), BPDA-SS: branched poly (β-amino ester) containing disulfide linkages, BBPE: poly-(β-amino ester), PEG-b-PLA: poly(ethylene glycol)-block-poly(D,L-lactide), DOPE: 1,2-di-octadecyl-sn-glycero-3-phospho-(1'-rac-glycerol), PEI: polyethylenimine, mPEG: methoxy poly (ethylene glycol), PLGA: Poly (lactico-co-glycolic acid), PCL: poly-(caprolactone), ABP: arginine grafted bioreducible poly (disulfide amine) polymer, γ-PGA: poly(γ-glutamic acid), PAMAM: poly(2-dimethylaminoethyl methacrylate), PLL: poly-L-lysine, polystyrene latex NPs, PLGA NPs) onto which the polyelectrolyte can be adsorbed with high yield and to avoid interparticle bridging and flocculation. It is also important to choose the appropriate polyelectrolyte concentration and ionic strength; otherwise, random, self-assembled aggregates of polycations and nucleic acids may suffer from severe aggregation when subjected to the high ion strength of biological fluids. Hence, the complex methodology and formulation ratio of LBL approach may limit the translatability and reproducibility of this approach.

3.2.3. Protection by core-shell encapsulation

Another alternative protection strategy is using core-shell encapsulation based nanocarriers. One of the critical developments is the introduction of Stable Nucleic-Acid Lipid Particle (SNALP). In general, SNALPs consist of modified RNAs, which is entrapped inside the bilayer membrane made up of cationic–zwitterionic lipids (helper lipid) with an outermost shield of PEG (Fig. 5A). The introduction of cholesterol or DOPE increased stability of NPs and PEG lipid improved the biosafety and pharmacokinetic characters, thus achieving the enhanced protection effects on RNAs during the systematic delivery.

To increase the RNAs entrapment inside the core of lipid NPs, siRNA was mixed with calf thymus DNA before complexing with protamine, and then coated with cationic liposomes, consisting of DOTAP, cholesterol and DSPE-PEG-anisamide to obtain Liposome-poly-2-chloro-7-dimethylaminonaphthalene-9-sulfonic acid DNA (LPD) particles [96]. The addition of calf thymus DNA and protamine in the formulation reduced the particle size by 10–30% and increased delivery efficiency by 20–80%. Besides, the increase in the overall negative charges on the RNAs with the simultaneous increase in the positive charges could provide better electrostatic interaction and encapsulation efficiency. Moreover, hyaluronic acid was also used to replace the calf thymus DNA into the formulations that provided multivalent charges to enhance the particle condensation, forming negatively charged complexes. Then, cationic liposomes were coated as shell to prepare the LPH NPs, which showed approximately 90% siRNA encapsulation efficiency [97]. Besides, the core-shell encapsulation strategy also puts forward advanced requirements for the preparation process. Wang group [98] used amphiphilic block copolymer of mPEG-PLA and the amphiphilic cationic lipid BHEM-Chol to fabricate a NP delivery system with siRNA encapsulation (Fig. 5C). The siRNA was encapsulated in the core by a non-condensation process and a double-emulsion solvent evaporation technique. This process and formulation achieved high siRNA encapsulation efficiency above 90% and the siRNA loading weight ratio was up to 4.47% [98].

Additionally, given the advantage of adjustable chemical structure, strong self-assembly ability and “all-in-one” function, polyionic complex (PIC) micelle (PM) consisted of two or more water-soluble copolymer with different charges is also an alternative core-shell encapsulation platform for RNA (Fig. 5D). For instance, the anionic double-hydrophilic block
copolymers, composed of PEG and a degradable carboxylic acid-functionalized polyanionic PCL block (PEG_{43}-b-PCL_{12}(COOH)_{6,5}) (DHBC), and the counter-polycation PLL were formed into PIC micelles for stably incorporating siRNA [99]. In this structure, the polycation block PLL complexed with siRNA to form a core, while the DHBC complexed with PLL/siRNA to form an outer shell that decreased the overall cytotoxicity by masking the excessive positive charges. In this way, RNAs could be encapsulated in the core of the PM after the spontaneous formation of an electrostatic complex between the polyanionic block and the polycation block. These resulting micelles showed good encapsulation efficiency on siRNA of 75% at a charge ratio R = 1, great biodegradability and biosafety.

Considering that polyelectrolytes under physiological salt levels might disrupt the stability of PM/RNA NPs by interfering with the charge-charge interaction among PIC, or between PM and RNAs, strategies to promote the stability of polymeric vectors-based micelles have been further proposed. (i) Controlling the chain rigidity of cationomers (e.g. introducing hydrophobic moieties in polycation segments [100]), or RNAs [101]. Horacio et al. [102] reported that the PIC micelles self-assembled by relatively flexible PEG-poly(glycidyl butylamine) (PEG-PGBA) block copolymer allowed more than 50-fold stronger binding to mRNA than those by the relatively more rigid PEG-PLL block copolymer, resulting in enhanced protection on mRNAs against enzymatic attacks. (ii) Preserving the micelle structure by cross-linking the core with stimuli-responsive covalent bonds. Kataoka et al. [103] introduced the disulphide bonds as the crosslink moieties into the PEG–PLL copolymers, thus attained tighter mRNA packaging in the PM core and improved mRNA nuclease tolerance in serum and intracellular spaces compared with non-crosslinked PMs. (iii) Compressing RNAs into the inner hydrophilic core of reverse micelles or vesicles stabilized by bilayer membrane core-shell NPs (Fig. 5B). Wei et al. [104] compressed siRNA into the inner hydrophilic core of reverse PCL-PEI micelles at a low N/P ratio of 5, followed by coating a neutral lipid membrane (DOPE, cholesterol, DSPE-PEG) to form negatively-charged core-shell NPs by microfluidic technology. These new Lipid/Polymer hybrid nanoassemblies exhibited stronger protection on siRNA locked in core and better stability in circulation with reduced usage of cationic PCL-PEI materials compared with traditional lipid/micelle/siRNA (LMS) NPs.

The core-shell type accounts for a large number of nanocarriers for RNA delivery and has been extended to the broader structural feature (e.g., ionizable cationic lipids-based LNP, as discussed in the section of 3.2.5). More efforts have focused on the structure optimization of materials and usage of facile preparation process to stably entrap RNAs in the core of nanocarriers. Moreover, controlled release at the targeted sites is also of great importance for core-shell type-based RNA delivery systems.

3.2.4. Protection by non-electrostatic interaction-based encapsulation

Although the electrostatic interaction-based encapsulation has been the mainstream for RNA delivery nanocarriers and exhibited great transfection efficiency since their positively-charged surface, these cationic NPs with excess positive charges are susceptible to rapid clearance due to non-specific interaction with anionic components in the blood and uptake by the mononuclear phagocyte system (MPS), and also tend to induce acute cytotoxicity, thereby limiting their therapeutic value. Recently, non-electrostatic interaction-based encapsulation strategies have been employed for RNA delivery, including complementary base pairing-based, hydrogen bonds forces-based, and coordination bond-based RNA delivery systems.

For example, nucleic acid drugs themselves can efficiently co-assemble with RNAs for co-delivery through complementary base pairing. Ding et al. [105] constructed the branched antisense DNA and siRNA co-assembled nucleic acid nanostructures, in which branched antisense (7AS) was synthesized through a copper-free click reaction between azide-modified β-cyclodextrin and DBCO-modified antisense. A siRNA with the 3’ overhangs as the linker (siRNA_3) was then recognized by one pair of branched antisense with seven arms (7AS1 and 7AS2), through DNA–RNA hybridization, to form the 7AS1/siRNA_3/7AS2 complex. Based on the host–guest interaction, an adamantane-modified folate molecule and an adamantane-modified influenza hemagglutinin

---

**Fig. 3.** Protection of RNAs from nuclease degradation by electrostatic adsorption. The common cationic nanovectors for RNAs delivery including (A) cationic lipids-based lipoplexes, (B) cationic polymers-based polyplexes, (C) PEG-based cationic block copolymer formed NPs, and (D) cationic amphipathic-based block copolymer formed NPs.
A peptide were included. This multifunctional nucleic acid nanostructure could function as both delivery carrier and therapeutic cargo to be released by intracellular RNase H digestion, avoiding the risk of systemic toxicity caused by cationic nanocarriers (Fig. 6A).

Similarly, Zhang et al. [107] constructed a spherical nucleic acid (SNA)-like nanogel assembled by a DNA-grafted polycaprolactone (DNA-g-PCL) brush and siRNAs as crosslinker via nucleic acid hybridization in which siRNAs were fully embedded and protected for systemic delivery (Fig. 6B).

In addition, the mild reaction of phenylboronic acid with 1,2- or 1,3-cis-diols to form esters also offers a facile route for binding siRNA to the PBA groups via the ribose ring at the 3’ end of RNAs. Shen et al. [88] designed a block polymer PEG-b-poly (benzoxaborole) (PEG-PBO), which could complex siRNA by forming pH-responsive boronic ester bonds with ribose rings of siRNA and adhere to the hydroxyapatite surface of CaP. The PEG-PBO/siRNA/CaP nanocomposites exhibited high siRNA loading efficiency (about 94% at the PEG-PBO to siRNA weight ratio of 20), low cell cytotoxicity and excellent colloidal stability at neutral pH (Fig. 6C).

The coordination interaction between metal (e.g., Ca$^{2+}$, Zn$^{2+}$, Fe$^{3+}$) and phosphate of RNAs is also widely used for RNA encapsulation. Based on Zn$^{2+}$-dipicolylamine complexes (Zn-DPA) that are highly selective for phosphodiester groups of siRNA, HA conjugate bearing 5β-cholanic acids and Zn-DPA was synthesized and complexed with siRNA to form HA$_{DPA-Zn}$-NPs, and it was demonstrated that 100 μg HA$_{DPA-Zn}$-NPs contained 15 pmol siRNA [87].
Taking advantage of hydrogen bonding and hydrophobic interactions for loading RNAs, Wang et al. [86] synthesized amphiphilic gemcitabine prodrug (GOA conjugate), and used the cytotoxic of gemcitabine to bind with miRNAs through hydrogen bond interaction of nucleobases. Then the GOA/miRNA complexes were further self-assembled into NPs with a hydrophobic interaction of tail chains. These NPs had a stable encapsulation on miRNAs with non-sequence selectivity and exhibited great biosafety after systematic administration (Fig. 6D).

Unlike most reported RNAs delivery systems, non-electrostatic interaction-based formulations do not need cationic derivatives to complex with RNAs. Usually, they are regarded as lower toxicity and less nonspecific accumulation than polycationic-based formulations. Whereas, compared with cationic nanocarriers, transfection efficiency is limited due to the less cell uptake or endosomal escape, besides, a detailed mechanism for the interaction of these RNA delivery systems with components in the blood circulation and cells needs to be verified, including formation of protein corona, cell internalization, and endosomal escape process. Furthermore, advanced evaluation methods are needed to be exploited for the non-cationic associated toxicity. In summary, the optimum balance between the safety and effectiveness is essential for the success of nanocarriers in RNAs delivery.

### 3.2.5. Protection by LNPs

Recently, numerous LNP-based nanocarriers have been developed for RNAs delivery and have exhibited great potential in the clinical translation, since their high delivery efficiency and low toxicity. More and more research interesting are focused on the design of various lipids and lipid derivatives, including primary and secondary amino lipids, tertiary amino lipids, lipidoids, lipid-derived lipopeptides and so on [108].

The great protection of ionizable cationic lipids-based LNPs toward RNAs depends on the morphology and encapsulation mechanism of LNPs, yet their structural features remain unclear. Pieter R. Cullis et al. [110] provided an understanding of the structure of LNP-siRNA systems containing DLinKC2-DMA, phospholipid, cholesterol and PEG lipid formed using a rapid microfluidic mixing process. The experimental results showed that these LNP-siRNA systems had an interior lipid core containing siRNA duplexes complexed to cationic lipid, phospholipid and cholesterol, which exhibited an electron-dense core (in contrast to bilayer vesicle systems). Meanwhile, along with the increasing siRNA concentration, more cationic lipid would be transferred from external lipid monolayer to the cavity to form complex with siRNA, suggesting that the siRNA contained in the inverted micelle was surrounded by an inner monolayer of cationic lipid. Consistently, molecular modeling also demonstrated that these LNPs had a nanostructured core consisting of periodic arrangement of aqueous compartments. This structure contained siRNAs and the polar moiety of the lipid to form inverted micelle, followed by association with “empty” inverted micelles (formed from excess ionizable lipid) to form a hydrophobic core which was further surrounded by helper lipids. Additionally, the PEG layer was presented in the outer layer to provide further shielding and protection. Such organization could account for the complete protection of encapsulated siRNA from external RNase.

Whereas, Pieter R. Cullis et al. [110] proposed another potential mechanism of LNPs formation by investigating the LNPs morphology changes during the siRNAs encapsulation process with pH changes. The initial event was formation of small vesicles which contained siRNA duplexes complexed to cationic lipid, phospholipid and cholesterol, which exhibited an electron-dense core (in contrast to bilayer vesicle systems). Meanwhile, along with the increasing siRNA concentration, more cationic lipid would be transferred from external lipid monolayer to the cavity to form complex with siRNA, suggesting that the siRNA contained in the inverted micelle was surrounded by an inner monolayer of cationic lipid. Consistently, molecular modeling also demonstrated that these LNPs had a nanostructured core consisting of periodic arrangement of aqueous compartments. This structure contained siRNAs and the polar moiety of the lipid to form inverted micelle, followed by association with “empty” inverted micelles (formed from excess ionizable lipid) to form a hydrophobic core which was further surrounded by helper lipids. Additionally, the PEG layer was presented in the outer layer to provide further shielding and protection. Such organization could account for the complete protection of encapsulated siRNA from external RNase.

Although the certain mechanism of formation and structural features of LNPs remain obscure, optimized LNP-RNA delivery system relies on the physiochemical characterization of formulations. Recently, various LNPs have been designed by the adjustment of pKa of ionizable lipid [111], the choice of helper lipids and the proportions of each lipid components [112] to improve stability and encapsulation efficiency on RNAs. It is worth noting that the structural-activity relationship of each lipid in different formulations is still needed to be studied in future.
With the breakthrough of LNPs in the success of mRNA vaccines against COVID-19, LNPs have received more and more attention. However, the obstacles like durability of vaccine efficacy were still remained. Moreover, LNPs can be designed to broaden application across other RNA therapeutics and diseases by improvement of targeting ability, enhancing loading capability, cell uptake, endosomal escape and ultimately delivery efficiency of RNAs.

Fig. 6. (A) Schematic illustration of the co-assembly of branched antisense and siRNA for combined gene silencing and tumor therapy in vitro and in vivo. FA: folate for targeting; HA: influenza hemagglutinin peptide for endosomal escape; 7AS1 or 7AS2: branched antisenses covalently cross-linked by β-CD; siRNA<sub>L</sub>: 3′ terminal extended siRNA; and ARA@NP: FA-7AS1/siRNA<sub>L</sub>/HA-7AS2 co-assembled by hybridization between functionalized branched antisenses and siRNA<sub>L</sub> [105]. Reproduced with the permission from Ref. 105. Copyright © 2021 John Wiley and Sons. (B) Illustration of crosslinked nanogel formation and the siRNA delivery in vivo [106]. Reproduced with the permission from Ref. 106. Copyright © 2018 John Wiley and Sons. (C) Assembly of PEG-PBO/siRNA/CaP hybrid nanoparticles and its pH responsive disassembly [88]. Reproduced with the permission from Ref. 88. Copyright © 2018 Royal Society of Chemistry. (D) The nucleobase head of GOA prodrug was proposed to bind to nucleobase of miRNAs with hydrogen-bond interaction, and the oleic acid tail chains could provide hydrophobic forces to self-assemble into GOA/miR nanoparticles in aqueous solution [86]. Reproduced with the permission from Ref. 86. Copyright © 2019 Elsevier.
3.3. Prolong circulation of RNA-loaded nanocarriers

In order to achieve effective targeted tissue accumulation and improve pharmacokinetic characters of RNAs, prolonged blood circulation time is necessary for RNA delivery system, and thus reduce dosing frequency and maintain effective concentrations over the desired period. The main challenge for long blood circulation time is capture of NPs by phagocytic cells of the MPS and rapid kidney clearance. Since phagocytic clearance of NPs is mediated by opsonization, which is attributed to the adsorption of plasma components (i.e., opsonin) onto the surface of a foreign NPs. The exact nature of the opsonin that adsorb onto NPs varies according to the size and surface characteristics of the NPs.

3.3.1. Surface modification of PEG (PEGylation) and its alternatives

PEGylation is a common strategy to prolong the blood circulation time of NPs. Hydrophilic PEG layer can provide a ‘stealth’ effect to NPs in vivo through shielding the surface to limit the adsorption of serum proteins, thereby prevent opsonization, and ensure protection NPs against mononuclear phagocyte capture and thus contributing to increased circulation time. PEG exists in surface of NPs with different conformations (Fig. 7A) depending upon the surface-grafting density, which ultimately determines the fate of nanocarriers [113]. Generally, higher PEG density on the surface of nanocarriers facilitates better steric barriers through the formation of brush-like conformations [114]. Besides, PEG can be grafted chemically or adsorbed physically on to the NPs or directly used during preparation of NPs (Fig. 7B). Adsorption of pre-formed PEG derivatives through non-covalent interactions or physical adsorption onto the surface of NPs generally weak to ensure complete PEG coverage [113]. Alternatively, they can also added as additives with amphiphilic structures, such as PEG-lipids conjugate or PEG block copolymers introduced during the preparation of NPs [115]. For traditional liposomes, PEG1000 to PEG2000 constituting 5–10%mol of total lipid is sufficient for PEGylation of liposomes [116].

Shi et al. [63] developed a lipid-polymer hybrid NPs composed of a cationic lipid (G0-C14)/siRNA complex-containing PLGA polymer core and a lecithin/lipid-PEG shell. The results showed that DSPE-PEG<sub>5k</sub> NPs, DSPE-PEG<sub>10k</sub> NPs and ceramide-PEG<sub>5k</sub> NPs exhibited the prolonged circulation of siRNA with a half-life (t<sub>1/2</sub>) of ~8.1 h, ~7.1 h and ~30 min, respectively. Whereas, the naked siRNA was rapidly cleared from blood within 30 min. Besides, both DSPE-PEG NPs demonstrated ~100-fold greater measurement for area under the curve (AUC) than that of naked siRNA, which demonstrated that the incorporation of PEG on the surface of NPs could efficiently improve the pharmacokinetic characters of RNAs.

Although a higher ratio of PEG enhances the circulation times, it hampers the efficient tissue penetration, cellular uptake and endosomal escape, which is usually regarded as the “PEG dilemma”. To circumvent this problem, cleavable PEG-lipids or polymers are introduced onto NPs, where PEGs are cleaved from NPs surface after PEGylated NPs reach targeted tissues (these contents would be discussed in the section of “3.5.1”). On the other hand, repeated administration of PEGylated NPs, especially liposomes, tends to result in accelerated blood clearance (ABC) phenomenon, which severely hinders the therapeutic efficacy. Briefly, upon the first injection of PEGylated liposomes, IgM antibodies are produced by activated B cells in the splenic marginal zone; the subsequently injected PEGylated liposomes then interact with the residual IgM antibodies in the serum, activate the complement and are finally taken up by macrophages [117].

To avoid the drawback induced by PEGylation, synthetic alternatives to PEG have been widely investigated, which mainly includes poly(glycerol) (PG), poly(2-oxazoline) (P2Ox), poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA), poly(vinylpyrrolidone) (PVP), biodegradable poly(aminoc acids) (e.g. PGA, poly(2-hydroxyethyl)-L-asparagine) (PHEA) [118], and zwitterion (e.g. phosphorylcholine) [119] (Table 6). Duvall’s group [120] synthesized a library of diblock polymers containing the same pH-responsive, endosomolytic polyplex core-forming block but different corona blocks: 5 kDa (benchmark) and 20 kDa linear PEG, 10 kDa and 20 kDa brush-like poly(oligo ethylene glycol), and 10 kDa and 20 kDa zwitterionic phosphorylcholine-based polymers (PMPC) for siRNA delivery (Fig. 8A). It was found that 20 kDa PEG and 20 kDa PMPC had the highest stability and were the most effective at blocking protein adsorption. Following intravenous delivery, 20 kDa PEG and PMPC coronas both extended circulation half-life 5-fold compared to 5 kDa PEG. Moreover, zwitterionic PMPC-based polyplexes showed highest in vivo luciferase silencing (~75% knockdown) and 3-fold higher average tumor cell uptake than 5 kDa PEG polyplexes (20 kDa PEG polyplexes were only 2-fold higher than 5 kDa PEG).

Although many alternatives to PEGylation have been proposed for several years, there are still difficulties to translate into clinical practice.

![Fig. 7. (A) Types of PEG conformations (B) techniques of linking PEG to NPs.](image-url)
Consequently, it is still in demand that search for other potential alternatives and further proper evaluation and comparison with PEG.

### 3.3.2. Altering physicochemical properties of the NPs

The physicochemical properties of NPs (including size [122–125], shape [126,127], elasticity [128], hydrophobic surface [121] and charge [129]) can also influence protein adsorption and blood circulation time [124].

| Types of alternatives | Name | Structure | Characters |
|-----------------------|------|-----------|------------|
| Poly(amino acid)s    | PGA  | ![PGA Structure](image) | decreased ABC clearance, biodegradability, complement activation |
| Polymers with Heteroatoms in the Main Chain | poly(hydroxyethyl-L-asparagine) (PHEA) | ![PHEA Structure](image) | |
| Polymers with Heteroatoms in the Main Chain | poly(glycerol) (PG), hyperbranched PG (HPG) | ![HPG Structure](image) | non-biodegradability, high degree of branching is advantageous for the circulation time and have low intrinsic viscosity |
| Polymers with Heteroatoms in the Main Chain | poly(2-methyl-2-oxazoline) (PMeOx), poly(2-ethyl-2-oxazoline) (PEtOx) | ![PMeOx Structure](image) | show a behavior comparable to PEG in terms of blood circulation time, opsonization, and organ distribution |
| Vinyl Polymers | poly(acrylamide) (PAAm) | ![PAAm Structure](image) | the monomer shows toxic side effects produced during thermal and photolytic degradation of the polymer |
| Zwitterionic polymers | poly(carboxybetaine) (pCB), poly(sulfobetaine) (pSB)-based polymers | ![pCB Structure](image) | PHPMA conjugates (e.g. PHPMA-doxorubicin copolymer) have already entered clinical trials |

It has been reported that for long-circulation of NPs, the size of NPs should be large enough to avoid renal filtration but small enough to minimize opsonization and MPS clearance, thus spherical particles of diameter between 10 and 200 nm appear to fit this description [124]. Wan et al. [125] successfully prepared a small orderly curled silica nanosheet (OCSN) (~42 nm particle size) with large continuous channels (~13.4 nm) for efficient siRNA loading. Because the diameter of the OCSNs was small enough, they exhibited a long blood circulation.
Fig. 8. (A) siRNA polyplexes containing varied corona architectures. All polymers contain the same polyplex core-forming block consisting of equimolar DMAEMA and BMA. The corona-forming blocks comprise either linear PEG, zwitterionic PMPC, or brush PEG structures (POEGMA), as pictured. Polymer structures are displayed on the left, with the core-forming block in red and corona-forming block in blue. Polymers are complexed with siRNA at low pH, triggering spontaneous assembly of polyplexes before the pH is raised to physiological pH [120]. Reproduced with the permission from Ref 120. Copyright © 2017 American Chemical Society. (B) Schematic illustration of the adsorption efficacy of serum proteins onto the surface of aOEI-C12 NAs and f0.7OEI NAs [121]. Reproduced with the permission from Ref 121. Copyright © 2018 American Chemical Society.
halftime (0.97 h) and low blockade efficacy in a mononuclear phagocytic system.

In addition, hydrophobic surface of NPs is another parameter for long-circulation properties, which could mediate NPs resistance against serum protein adsorption. Considering hydrophobicity of fluorinated chain, Liang et al. [121] fabricated a library of perfluorooctanoyl-serum protein adsorption. Considering hydrophobicity of fluorinated long-circulation properties, which could mediate NPs resistance against the fenestrae of the liver capillaries (hydrodynamic diameter over 230 nm) to prevent it from passing through the Space of Disse, thus hindering its ability to interact with hepatocytes. The study demonstrated that the pretreatment of mice with the Nanoprimer decreased the LNPs’ uptake by the MPS and prolonged the circulation time of LNPs. By accumulating rapidly in the liver cells, the Nanoprimer improved the bioavailability of the LNPs encapsulating human erythropoietin (hEPO) mRNA or factor VII (FVII) siRNA, leading respectively to more hEPO production (by 32%) or FVII silencing (by 49%).

3.4. Enhance accumulation of RNAs at targeted tissue/organ

To achieve high therapeutic efficiency of RNAs, precise delivery and accumulation of RNAs at targeted tissue/organ are of importance for delivery systems. Although the approvals of Patisiran and GalNac-siRNA have made great progress in the liver-targeting therapy field, other tissues or organs accumulation for RNA delivery systems remain challenges in clinical application. There are a large number of non-targeted RNA-loaded NPs in clinical trials have failed due to insufficient delivery to the target sites [137].

3.4.1. Ligands modification of NPs

To enhance tissue/organ accumulation of RNAs, the most commonly used method is targeting ligands modification onto the RNA-loaded nanocarriers, which can achieve receptors-ligands binding-mediated accumulation strategy at targeted tissue/organ according to the expression of specific receptors on targeted tissues of different disease states. Currently, different types of ligands are applied to the delivery systems, and generally contains peptides, antibodies, and other biologically active small molecules (like lactobionic acid, folate and mannose).

Table 7

| Targeted tissue/organ | Nanocarriers components | Ligands | Ref |
|-----------------------|--------------------------|---------|-----|
| Mantle cell lymphoma  | Dlin-MC3-DMMA, cholesterol, DSPC, DMG-PEG, and DSPe-PEI | Anti-CD38 monoclonal antibodies | [138] |
| (MCL)                 |                          |         |     |
| Lymphoma              | PEG-maleimide, siRNA     |         | [74] |
| Acute myeloid leukemia | siRNA, DOTAP, DOPE, cholesterol, albumin NPs, all-trans retinoic acid (ATRA) |         | [139] |
| Liver                 | siRNA, DSPE-PEG-pPB, DlinMC3, PEG-DMG, DSPC, cholesterol | pPB peptide (C’SRSNLDC^+^) | [140] |
| Brain, Neurons         | siRNA, NL4 peptide and ApoA-I modified dendrigrift PLL (DGL) (generation 3) | TF | [142] |
| Colorectal cancer      | SenPs, siRNA, RGDC peptide |         | [143] |
| Prostate cancer        | HPAA-PEG-APT, siRNA     |         | [144] |
| Malignant melanomas    | DC-Chol, DOPE, siRNA, ASI1411-PEG-DOPE | Anti-PSMA aptamer Aptamer ASI1411 | [145] |
| Prostate cancer        | siRNA, Adamantane-Peg, Dlysine-cycloexdine, Epoide-Based Lipidoids (C12-SPM), DSPC, cholesterol, C16-PFG40-Ceramide, s-galactosyl ceramide, siRNA | Anisamide | [146] |
| Liver                 |                          |         | [147] |

Abbreviation: RGDFC: Cyclo (Arg-Gly-Asp-D-Phe-Cys).

3.3.3. CD47 modification of NPs

As well known, the CD47 marker on red blood cells (RBCs) prevents RBCs from phagocytosis by macrophages via interactions with the inhibitory receptor SIRPα on macrophage membranes. Inspired by natural CD47–SIRPα pathway, which CD47 serves as a “don’t eat me” signal and a “marker of self” to achieve phagocytosis evasion by macrophage, CD47-contained delivery systems are developed for improving circulation time by reducing MPS clearance [133]. For example, a PLGA NP conjugated with CD47 extracellular domain via reactive oxygen species (ROS)-resistant phenylborate ester bond was developed. The experimental results showed that the NPs efficiently increased half-life of payload in blood circulation by preventing engulfment of NPs via phagocytosis [134]. Although the above nanocarrier is not used for RNA delivery, the CD47-based strategy of preventing MPS phagocytes may be universal. Moreover, CD47-contained biomembrane was also used to camouflage NPs for prolonging circulation time.

3.3.4. Nanoprimer pre-treatment

As reported, the MPS, previously known as the reticuloendothelial system (RES) [135], are mainly present in liver tissues, and in particular Kupfer cells (KCs) and liver sinusoidal endothelial cells (LSEC) usually take up a significant part of LNPs administered systemically, leading to the decreased circulation time of NPs.

To avoid this capture, a Nanoprimer was administered to transiently occupy MPS prior to the RNA nanocarriers was employed [136]. The Nanoprimer is a liposome designed with specific physicochemical properties to transiently occupy the KC and LSEC, which does not contain or encapsulate any drug nor have any moieties attached to its surface. Besides, the Nanoprimer was optimized to be larger than the fenestrae of the liver capillaries (hydrodynamic diameter over 230 nm) to prevent it from passing through the Space of Disse, thus hindering its ability to interact with hepatocytes. The study demonstrated that the pretreatment of mice with the Nanoprimer decreased the LNPs’ uptake by the MPS and prolonged the circulation time of LNPs. By accumulating rapidly in the liver cells, the Nanoprimer improved the bioavailability of the LNPs encapsulating human erythropoietin (hEPO) mRNA or factor VII (FVII) siRNA, leading respectively to more hEPO production (by 32%) or FVII silencing (by 49%).
The examples of usage of ligands onto the NPs are exhibited in Table 7. Kataoka et al. [148] used a glucosylated-polyion complex micelle (GLu-PIC/Ms) self-assembled from glucosylated-PEG-b-PLL modified with 3-mercaptopropyl amine and 2-thiolaneimine (PEG-PLL(MPA/IM)) block copolymer and ASO through electrostatic interaction as the platform structure for the BBB-crossing nanocarrier. This glucose-coated nanocarrier could be bound by glucose transporter-1 (GLUT1) expressed on the brain capillary endothelial cells and then could be delivered to the brain by crossing the BBB using glycemic control as an external trigger. The results showed that this nanocarrier efficiently acumulated in the brain tissue 1 h after intravenous administration and exhibited significant knockdown of a target long non-coding RNA (IncRNA) as high as 40%.

Different from traditional receptor-ligand recognition strategies, Dan Peer et al. [11] employed a conformation-sensitive targeting strategy that only recognized a specific protein conformation, namely the high-affinity conformation. Since α4β7 integrin expressed in leukocytes always change conformation and dramatically increase the affinity for their ligands (MadCAM-1) when it is still anchored, a recombinant fusion protein, which fused the integrin binding domains D1 and D2 of the MadCAM-1 to an IgG–Fc, was generated and conjugated to the surface of LNPs as a targeting moiety. These LNPs achieved in vivo gene silencing in a selective subset of leukocytes and showed potential therapeutic applications in a murine model of colitis. Since the relationship between conformational state and protein functionality is a commonly seen phenomenon, targeting specific conformations of proteins opens new avenues in LNP targeting strategies. However, on a molecular level, little is known about the protein-driven, inside-out signaling processes that result in such conformational changes. In addition, the environment in vivo is more complex, and the study of conformation dynamics is more limited.

3.4.2. SORT molecular-based LNPs

Since the tissue selectivity and organ tropism of delivery systems can be also influenced by the surface potentials and/or internal charges of nanoparticles, altering the surface property (like charge) of NPs to specifically accumulation into the targeted the organ or tissues have been extensively investigated. For example, Daniel J.’s group [149] reported a strategy termed Selective Organ Targeting (SORT) that allowed accurate delivery of diverse cargoes including mRNA, Cas9 mRNA/single guide RNA (sgRNA) and Cas9 ribonucleoprotein (RNP) complexes to the lungs, spleens and livers following intravenous (i.v.) administration via incorporation of differentially charged phospholipids into the LNP formulation. (Fig. 9A). The results found that with an increasing molar percentage of permanent cationic lipid SORT molecules TrotAP, the resulting LNP moved progressively from liver to spleen, and then to lung, demonstrating a clear and precise organ-specific delivery trend. When added 50% of TrotAP into the formulations, 80% of the LNPs accumulated in lung. Whereas with the incorporation of 10–40% anionic lipid SORT molecules (1,2-dioleoyl-sn-glycero-3-phosphate, 18PA), LNPs mediated completely selective delivery to the spleen. With the addition of ionizable cationic lipid (1,2-dioleoyl-3-dimethylammonium-propane, DODAP), the LNPs significantly enhanced liver delivery > ten-fold at 20% incorporation and transacted ~93% of hepatocytes. The results suggested that altering the internal and/or external charges of NPs may be a key and universal strategy in tuning tissue tropism. In addition, determining the precise mechanisms that explain how SORT enabled the tissue targeting may be the next research point. In a follow-up to this study, Daniel J. et al. [153] synthesized a library of zwitterion ionizable phospholipids, termed “iPhos”, which consist of one ionizable amino group and one phosphatase head group with three hydrophobic lipid tails. Then iPhos lipids synergistically functioned with various helper lipids to formulate mRNA-LNPs (called iPLNPs), and structure–activity relationships revealed that iPhos chemical structure could control in vivo efficacy and organ selectivity. The results showed that alkyl length next to the phosphate group influenced organ selectivity: Shorter chains (9–12 carbons) showed mRNA translation in liver, while longer chains (13–16 carbons) would transfer protein expression to spleen. The detailed mechanistic studies still need to be performed (Fig. 9B).

Therefore, the rationally designed nanocarriers with optimized characters by detailed in vivo structure-activity relationship study will provide translational potential for RNA targeted delivery to realize clinical applications.

3.4.3. Immune cell-mediated hitchhiking NPs

Considering that massive immune cells infiltration and accumulation is usually a key feature for lesion tissue, taking advantages of oriented migratory properties of immune cells to design hitchhiking NPs is another tissue/organ targeting and accumulation strategy. For example, certain cell types have the intrinsic ability to cross the endothelial barrier and infiltrate the tumor tissue, like T cells can identify and migrate to the tumor tissue, which makes them attractive carriers for NP delivery. Stefaan group [154] developed the lipid-enveloped nanogels (siNGs) consist of siRNA-loaded cationic nanogel (NG) core and pyrrolydilidithiopropionate (PDP)-functionalized liposomes as the outer shell, and subsequent attached the siNGs to the surface of cytotoxic CD8+ T lymphocytes (CTLs) based on disulfide bone formation between exofacial thiol present on the CTL plasma membrane and thiol-reactive liposomes (Fig. 9C). Then CD8+ T cells-carried siNGs would transport to the tumors and enhance the accumulation/infiltration of NPs based on intrinsic targeting ability of T cells to migrate to the tumors. Nevertheless, the T Cell-mediated targeting delivery capability are still to be investigated in future research.

Recently, increasing tendency in research works have focused on developing hitchhiking NPs by chemistry conjugation with immune cells, especially for small molecular therapeutics delivery, and few study for macromolecular therapeutics like RNA have been reported. Moreover, the coupling stability, potential influence on cell functionalities, detachment of nanocarriers from cell surface and subsequent intracellular release, and in vivo efficacy evaluation still need to be considered in the future.

3.4.4. Tuning the physicochemical characteristics of NPs

As well known, the physicochemical characteristics (size [155], surface charge [156], particle shape and rigidity/flexibility [157] of structures) play critical roles in tissue penetration and accumulation capability. Generally, small-size NPs have good tissues (e.g., tumor) permeability, while large-size NPs have good tissue accumulation and retention ability. Additionally, negative or neutral charged surface benefits the long blood circulation of the nanocarriers and achieves a high tumor accumulation. While the positive charge will promote the tissue penetration and cell uptake of the nanocarriers. To address the above conflicting need and enhance tissue penetration and accumulation, stimuli-responsive size and charge changeable NPs were developed for RNA delivery. For example, Chen et al. [156] designed a charge conversion multifunctional nanoplatform based on a pH-sensitive copolymer mPEG-PLL-2,3-dimethylaconitate anhydride (DMA) (PLM) and PAMAM dendrimers. The small-sized PAM/siRNA complexes built via electrostatic interaction were as the inner core and then PLM was applied as an outer layer with negative charges. Under a physiological environment, the PLM/PAM/siRNA complexes showed prolonged circulation time and enhanced tumor accumulation. While in the tumor microenvironment, the pH-triggered PLM cleaved into positive charge due to the cleavable amide bond between mPEG-PLL and DMA, leading to large-size NPs with a negative charge that turned into a positive charge and small NPs with a high tumor-penetrating ability.

In addition, for the deep tissue permeation and accumulation of nanocarriers, paracellular and transcellular pathways have also been considered for the development of RNA delivery systems. Whereas paracellular RNA delivery may be unlikely since intercellular gaps (5–10 nm) [155] are not large enough for large molecular RNA (like
Fig. 9. (A) Addition of a supplemental component (termed a SORT molecule) to traditional LNPs systematically alters the in vivo delivery profile and mediates tissue-specific delivery as a function of the percentage and biophysical property of the SORT molecule [150]. Reproduced with the permission from Ref 151. Copyright © 2021 Springer Nature. (B) iPhos lipid design directs LNP tissue targeting. Zwitterionic iPhos lipids contain two lipid tails on the positively charged tertiary amine and one lipid tail on the negatively charged phosphate group. Varying the alkyl lipid chain length impacts tissue targeting to liver, lung and spleen, which has been coined selective organ targeting (SORT) [151]. Reproduced with the permission from Ref 151. Copyright © 2021 Springer Nature. (C) Schematic representation of the formation of a disulfide bond between PDP-functionalized lipids that are incorporated into the liposome bilayer and reduced exofacial thiol groups, present at the cell surface [152]. Reproduced with the permission from Ref 152. Copyright © 2016 Elsevier.
siRNA (~5 nm) to pass through. For the purpose of achieving transcellular accumulation of RNAs into deep tissues, the nanocarrier is preferred to be as small as possible and needs to introduce ligands with transcytosis (consecutive endocytosis/exocytosis events) activity like transferrin (Tf). Takuzo et al. \[158\] developed a small-sized Tf-appended nanocaplet (\(\text{TfNC} \supset \text{siRNA}\)) for the purpose of realizing siRNA delivery into deep tissues. For obtaining \(\text{TfNC} \supset \text{siRNA}\), a macromonomer (AzGu) bearing multiple guanidinium (Gu\(^+\)) ion units, azide (N3) groups, and trityl (Trt)-protected thiol groups in the main chain, side chains, and termini, respectively, was designed and adhered to siRNA strand based on a multivalent Gu\(^+\)-phosphate salt-bridge interaction. After I\(_2\) was added to the preincubated mixture of AzGu and siRNA, oxidative polymerization of AzGu took place along the siRNA strand to obtain the \(\text{A}^\text{NC} \supset \text{siRNA}\), and this conjugate was converted into \(\text{Glue/BP} \supset \text{siRNA}\) by the click reaction with a Gu\(^+\)-appended bioadhesive dendron (Glue) followed by a benzophenone derivative (BP). Then, Tf

---

**Fig. 10.** (A) Synthesis of a siRNA-containing nanocaplet appended with transferrin (Tf) units (TfNC \(\supset\) siRNA) \[158\]. Reproduced with the permission from Ref. 158. Copyright © 2019 American Chemical Society. (B) Permeation of TfNC \(\supset\) siRNA into cells located in a deep tissue via Tf-mediated transcytosis. Once TfNC \(\supset\) siRNA escapes from the endosomes in a cell, glutathione (GSH), abundantly present in the cytoplasm, liberates siRNA to cause RNAi by reductive depolymerization of the nanocaplet part (TfNC) \[158\]. Reproduced with the permission from Ref. 158. Copyright © 2019 American Chemical Society. (C) Illustration of transmucus and transmembrane siTNF-\(\alpha\) delivery mediated by fluorinated and guanidinated bifunctional helical polypeptides \[159\]. Reproduced with the permission from Ref. 159. Copyright © 2020 American Chemical Society.
was covalently immobilized onto Glu/HBP NC ⊃ siRNA by Gu+ -mediated adhesion followed by photochemical reaction with BP. The resulting TiNC ⊃ siRNA nanocaplet showed a hydrodynamic diameter (Dh) of 15.8 ± 5.0 nm and permeated deeply into a cancer spheroid at a depth of up to nearly 70 μm with the help of Ti-induced transcytosis (Fig. 10).

In addition, the rigidity/flexibility of NPs is also a key factor for tissues permeability and accumulation. The rigid structures of the nanocarriers are considered to prevent penetration into deeper regions within tumor tissue [157]. While a flexible nanocarrier can be deformed during the paracellular transport, facilitating the intratumoral accumulation. For example, a siRNA-loaded non-cationic soft polyphenol nanocapsule called Nanosac was developed by sequential coating of MSN with siRNA and polydopamine, followed by removal of the sacrificial MSN core to produce a hollow structure [157]. The results of intravital confocal microscopy showed that the mean fluorescence intensity (MFI) of soft Nanosac in the tumor spheroid was 2-fold higher than that of hard NPs (MSN-cy5/pD), indicating that the soft NPs with flexible structure could improve penetration and accumulation of RNAs at tumors compared to hard counterpart.

3.4.5. Exogenous helper assisted tissue penetration

For enhance accumulation of nanocarriers at targeted tissue/organ, especially tumors, although the enhanced permeability and retention effect (EPR) of solid tumors was proposed and used for varieties of nanocarriers. However, it had been reported that the median delivery efficiency of NPs by EPR in solid tumors was only 0.7% by surveying the literature from 2006 to 2016 [160]. Thus, exogenous helper assisted tissue penetration approaches such as high-intensity focused ultrasound (HIFU) and continuous wavelength laser-induced photothermal effect, tissue penetration approaches such as high-intensity focused ultrasound (HCLR) was obtained. The results demonstrated that much more fluorescence could be found in the deep region of HCLR treated tumor in vivo via both active transmembrane fusogenic functional NPs can directly delivery RNAs to cytoplasm via fusing with the cellular membrane, which enhance cellular internalization and avoid endocytosis. Most synthetic carriers that can directly reach the cytoplasm through membrane fusion are preparations containing lipids. For example, some researchers combined fusogenic lipids (DMPC) with solid porous silicon nanoparticles (pSiNP) cores, loaded siRNA into pSiNPs via calcium ion precipitation, and showed that the uptake mechanism could be engineered to be independent of common receptor-mediated endocytosis pathways [170]. Marco et al. [171] also analyzed the composition and proportion of lipids and concluded that factors such as surface charge and particle size would affect the occurrence of membrane fusion, thus affecting the transfer of various nucleic acids. Since most membrane fusion is mainly a process driven by physicochemical properties of particles and plasm membrane, the fusion efficiency is basically irrelevant to cell types. However, it has also been suggested that there is a receptor-mediated membrane fusion process, allowing membrane fusion to act in an active-targeting manner as well.

3.5. Enhanced cellular internalization

As well known, effective cell internalization is the prerequisite for RNAs to exert gene therapy effects. Since the repulsion between the negatively charged RNAs and cell membrane hinders the efficient cell uptake of RNAs, different strategies were used to enhance cellular internalization.

3.5.1. Stimuli-responsive detachable PEG shell

One of the most widely used strategies is to incorporate cationic materials such as cationic polymers (CS, dendrimers, PEI, PLL, and et al.) and lipids (DOTAP, DOTMA, DOPE and et al.) in the delivery system to construct cationic nanocarriers, which can facilitate cellular internalization via electrostatic interaction. However, they always exhibit high levels of cytotoxicity due to their high positive charge density. Therefore, PEG-shielding strategy was widely applied in the cationic nanocarriers to mask the excessive positive charges on the surface of NPs, but the high PEG density would suppress the cellular uptake of nanocarriers. As such, stimuli-responsive detachable PEG shell with cleavable linkers was introduced to the nanocarriers for improving cell internalization. Generally, acid [162,163]or MMP enzymes [162,164,165] responsive-sheddable PEG shell were used. For example, Wang et al. [166] reported an acid-degradable amide bond (DiLmκm) linked PEG-DiLmκm-PLGA block copolymer and used to encapsulate siRNA into NPs (PEG–NPPLGA/siRNA) through the cationic lipid-assisted double emulsion method. The siRNA-encapsulating NPs prepared by PEG-b-PLA (NPPLGA/siRNA) and PEG-b-PLGA (NPPLGA/siRNA) were used as the control formulations. When the PEG–NPPLGA/siRNA achieved accumulation in tumor sites, the PEG surface layer was detached in response to tumor acidic microenvironment, leading to the changes of surface potential from neutral to positive with the exposure of cationic amino groups (Fig. 11A). The results demonstrated the increased cellular uptake by ~2 fold in contrast to NPPLGA/siRNA and NPPLGA/siRNA. Similarly, the PEG derivative O′-mPEG conjugated with lipid by pH-sensitive imine bond was used as a cleavable PEG-lipid to coat on the miRNA-loaded solid LNPs (SLNs) modified with cell-penetrating peptides. After the cleavable PEG layer was responded to low extracellular pH, the CPPs were exposed to improve the cell uptake [167].

3.5.2. “Armchair” structure constrained lipid-based LNPs

In addition to conventional strategy of enhancing cell internalization by increasing positive charge of nanocarriers, “armchair” structure based conformationally constrained lipids, which contained adamantane tail and formed stable constrained LNPs (cLNPs), was also found to enhance siRNA delivery to T cells [169]. The results showed that adamantane-containing LNPs could enable the LNPs massive accumulation in splenic T cells in vivo.

3.5.3. Cell membrane fusogenic functional NPs

Cell membrane fusogenic functional NPs can directly delivery RNAs into cytoplasm via fusing with the cellular membrane, which enhance cellular internalization and avoid endocytosis. Most synthetic carriers that can directly reach the cytoplasm through membrane fusion are preparations containing lipids. For example, some researchers combined fusogenic lipids (DMPC) with solid porous silicon nanoparticles (pSiNP) cores, loaded siRNA into pSiNPs via calcium ion precipitation, and showed that the uptake mechanism could be engineered to be independent of common receptor-mediated endocytosis pathways [170]. Marco et al. [171] also analyzed the composition and proportion of lipids and concluded that factors such as surface charge and particle size would affect the occurrence of membrane fusion, thus affecting the transfer of various nucleic acids. Since most membrane fusion is mainly a process driven by physicochemical properties of particles and plasm membrane, the fusion efficiency is basically irrelevant to cell types. However, it has also been suggested that there is a receptor-mediated membrane fusion process, allowing membrane fusion to act in an active-targeting manner as well.

3.5.4. Ligands functionalized NPs

Ligand modification is commonly used to promote cellular uptake along with cell targeting via ligand-receptor mediated mechanism. The ligands can be the antibodies (e.g., EGFR, VEGF), aptamers (e.g., AS1411), peptides (e.g., Cyclom(Gly-Asp) (eCGD), cell-penetrating peptides NRP-1), and bioactive small molecules (e.g., mannose, fucate, asindine) etc. For example, Lee et al. [172] reported the engineered LNP formulations for the targeted delivery of RNA into different
types of cells in the liver by screening the content of incorporation of active targeting ligands. The results showed that incorporation of mannose to LNPs with high PEG-lipid content (3%) allowed selective delivery of mRNA/siRNA only to liver sinusoidal endothelial cells (LSECs) through mannose-CD206 interaction. Additionally, incorporation of peptides that specifically bind to a receptor that is highly expressed on the target cell is commonly used for enhancing cellular internalization. Besides, cell-penetrating peptides (CPPs) are oligopeptides consisting of 10–30 amino acid residues that have excellent membrane permeability [173]. CPPs typically have a large number of arginine (Arg) residues in their primary structures, and the guanidinium groups of the Arg residues are crucial to the penetration efficiencies of CPPs by forming bidentate hydrogen bonds with negatively charged carboxylic, sulfate, and phosphate groups of lipids, glycoproteins (GAGs) or other cell membrane constituents [174]. Kim et al. [175] constructed a CPP with nine arginines (with positive charge) and a macrophage-targeted TKPR (Thr-Lys-Pro-Arg) sequence specifically binding to the neuropilin-1 (NRP-1) receptor on the macrophage surface, and used this peptide to bind with siRNA to form cationic complexes for macrophages-targeted delivery. In addition to the critical roles of guanidine groups of CPPs, peptide conformation and hydrophobic content also have significant effects on CPP’s penetration efficiencies. Several well-known CPPs, such as Pep-1, MPG, TP10, and melittin, either adopt inherent helical structures or form helices in the cell membranes, presenting a rigid amphiphilic structure to interact with the lipid bilayers to promote membrane permeation [176]. Yin et al. [159] developed a series of guanidinated and hydrophobic fluorinated bifunctional polypeptides with stable α-helical conformation for the

Fig. 11. (A) Scheme illustration showing the preparation of NP_{PLA/siRNA}, NP_{PLGA/siRNA}, and dPEGNP_{PLGA/siRNA} with PEG_{5K-b-PLA_{11K}, PEG_{5K-b-PLGA_{11K}} and the tumor pH-labile linkage-bridged block copolymer PEG_{5K-Dlink_m-PLGA_{11K}}. Compared with NP_{PLA/siRNA and NP_{PLGA/siRNA}}, dPEGNP_{PLGA/siRNA} can enhance tumor cell uptake by detaching the PEG layer and accelerate intracellular siRNA release with hydrophobic PLGA layer [166]. Reproduced with the permission from Ref. 166. Copyright 2016 ELSEVIER. (B) Schematic illustration of constructing the Nb-modified nanogel (Nb-nanogel) [168]. Reproduced with the permission from Ref. 168. Copyright 2020 ELSEVIER.
pulmonary delivery of siRNA (Fig. 10C). The α-helical polypeptides were synthesized by modifying the side chains of the polypeptide PPOBLG with azido guanidine and different azido fluorocarbons via click chemistry. Similar to the structure of natural CPPs, the guanidine groups and α-helix could render strong cell membrane penetration, and fluorocarbon modification of the polypeptides further enabled transmucous penetration, which dramatically enhanced the mucus permeation capability and cell internalization by ~240 folds.

Additionally, the wide availability and selectivity of monoclonal antibodies (mAbs) makes them a desirable strategy. The functional moieties upon the mAbs were commonly covalent conjugated with functional groups on the surface of the nanocarriers to provide the desired targeting features. In this way, several studies have demonstrated the targeted delivering RNAs preferentially to the desired cell subsets including cancer cells and notoriously hard to transfect leukocytes [177]. In addition, Camelid-derived single domain antibody fragments, commonly known as nanobodies (Nbs), which is the smallest naturally occurred antibody with recognition capacity against diverse antigen epitopes in nanomolar range. Due to their small size and unique structure, Nbs exhibit great advantages including flexibility to engineer, better solubility, chemical stability, low immunogenicity, and easy preparation. Zhu et al. [168] constructed a miRNA-embedded nucleic acid nanogel consist of DNA-g-PCL brush and crosslinkers miRNA-34a, and synthesized a short DNA segment with complementary sequence conjugated to the cysteine of nanobody (7D12) against EGFR at its C-terminal (Fig. 11B). By simply mixing the nanogel and Nb-DNA conjugates, the Nb-functionalized nanogel (Nb-nanogel) was formed and greatly promoted the accumulation at the tumor site and cellular uptake efficiency both in vitro and in vivo experiments.

Nevertheless, these chemical conjugation methods easily lead to damaged antibody functionality. Distribution of the antibodies’ functional groups, both at the variable and the conserved regions, can cause a random orientation of mAbs upon the nanocarriers. These limitations cause a significant reduction in targeted delivery capabilities [178]. Besides, their clinical translation was also hindered because of the high batch-to-batch variability of current technologies, which rely on chemical conjugation. In addition to chemical conjugation, Dan et al. [179] developed a recombinant membrane-anchored lipoprotein (anchored secondary scFv enabling targeting, named ASSET), which was incorporated into siRNA-loaded LNPs and interacted with the antibody crystallizable fragment (Fc) domain. ASSET was composed of two functional domains—an N-terminal signal sequence followed by a short CDQSSS peptide NlpA motif that undergoes lipidation in bacteria and the scFv of a monoclonal antibody (clone RG7/1.30) that binds to the Fc constant region of Rat IgG2a antibodies.

However, several reports indicated that the use of ligands usually does not prevent liver and spleen uptake of NPs. Proteins from the plasma or serum were reported to absorb onto the surface of NPs, forming a protein corona that might mask the ligand attached to the NPs [180]. In the future, the development and expansion of the protein database, peptide and aptamer libraries could be useful for the RNAs targeting intracellular delivery. Furthermore, the influence of these ligands modification on the in vitro fate of nanocarriers still need to be investigated.

3.6. Avoid intracellular lysosomal degradation

Avoiding RNA drugs degradation by lysosomes is one of the most important responsibilities of the RNA nanocarriers. After RNA nanocarriers are uptaken by cells, intracellular pathways will be different according to cell types, nanocarrier properties, particle concentration, etc., and the entry mode of particles will also affect the subsequent intracellular pathways to a certain extent. Endosomal-lysosomal pathway is the most common intracellular transport pathway for NPs after entering cells. Since the low pH and enzymatic environment of lysosomes have strong damaging effects on RNA, Therefore, avoiding the degradation of RNA drugs by lysosomes is particularly important to ensure that RNA drugs reach the cytoplasm to exert their efficacy. At present, the existing design strategies for increasing the arrival of RNA to the subcellular target site can be roughly divided into two categories: One is the escape from the degradative pathway–endosomal/lysosomal escape strategy; the other is the bypass of the degradation pathway (non-degradable pathway) – the strategy of changing intracellular trafficking pathways.

3.6.1. Rapid escape from endosomes/lysosomes

Commonly used endosomal/lysosomal escape mechanisms can be roughly summarized as follows: membrane rupture, membrane destabilization and formation of membrane pores, membrane fusion, etc. Different mechanisms can be implemented through carrier materials with different characteristics.

Most classic and widely accepted hypothesis of endosomal/lysosomal escape by membrane rupture is the “proton sponge effect”, which is caused by the imbalanced osmotic pressure between endosomal/lysosomal lumen and cytoplasm. The endosomal/lysosomal escape behaviors of nanocarriers containing cationic lipids such as DOTAP, cationic polymers such as PEI and PAMAM, and calcium phosphates can be explained by “proton sponge effect”, which usually have ionizable amine groups and strong buffering capacities in the pH range of 5 to 7. However, the exact mechanism of “proton sponge effect” is still being debated [181]. Besides “proton sponge effect”, Vesicles containing gas that can release gas in acidic lumen triggered by ultrasound, laser or acid are proposed to break the endosomal compartments as well through membrane rupture [182]. To enhance bioavailability and improve endo/lysosomal escape of siRNA, Xu et al. [183] developed pH-activated NPs for augmented cytosolic delivery of POLR2A siRNA (siPol2). The core material of designed NPs was CS with a side chain of guanidine (CG). The guanidinate could be reversibly combined with CO2 and the guanidine groups and amino groups on CS could bind with negatively charged siRNA. Under neutral conditions, it combined with CO2 to form carbonate, which could then be released under acidic conditions, thus inducing endosomal membrane rupture.

The occurrence of membrane destabilization and formation of membrane pores mostly involves CPP components. CPPs with amphiphilic and high positive charge characteristics [184], such as TAT peptides and other arginine-rich CPPs, can achieve endosomal/lysosomal escape of RNA drugs through membrane destabilization and membrane perforation. In the acidic endosomal compartment, the perforated peptide undergoes a conformational change by forming the α-helical structure, and then inserts into the hydrophobic region of the endosomal membrane and induces the formation of pores. The electrostatic interaction between positively charged CPPs and negatively charged endosomal membranes caused the instability of the membrane, achieving the endosomal/lysosomal escape of RNAs. The membrane destabilization ability of CPPs can be enhanced by screening and optimizing peptides, which is influenced by the sequence and length of amino acids [185].

The nanocarriers that can achieve endosomal/lysosomal escape through membrane fusion mostly mediated by fusion lipids together with cationic lipids. After the nanocarrier reaches the endosome, the cationic lipid can interact with the endosomal membrane rich in anionic lipids through electrostatic interaction. After that, the fusion lipid (such as DOPE) makes the lipid phase transform into an inverted hexagonal conformation [186], so that the fusion lipid is inserted into the endosomal membrane to realize the membrane fusion process.

3.6.2. Adjusting intracellular trafficking pathways of NPs

Another approach to avoid lysosomal degradation of RNA drugs is changing intracellular trafficking pathways. Some researchers believe that NPs entering cells via caveolin or macropinocytosis can bypass lysosomes and be directly transported to the endoplasmic reticulum (ER) or golgi apparatus. However, this statement has been questioned by some scholars. It is believed that the intracellular pathway of particles
after entering the cell is related to a variety of factors. The current research in this field is still relatively scarce, and differences in particle types and cell lines will affect the conclusion as well. Therefore, it cannot be directly affirmed or denied such relevance. Studies have used ER retention signal motif KDXX or KDEL peptide to modify carriers to realize cargos’ transport to ER [187, 188]. Our group previously designed ER membrane-decorated hybrid nanopollexes that altered the intracellular pathway of siRNA. ER isolated from cancer cells was used to fabricate an integrative nanopollexes to alter the traditional intracellular pathway of vectors based on cationic lipid. After entering cells, siRNA was transported through endosome-Golgi apparatus-ER pathway. In this process, functional proteins on the ER membrane such as SNARE proteins and proteins bearing KDEL signal peptide played important roles on altering intracellular trafficking pathway of siRNA. This EM-decorated hybrid lipopollexes significantly improved gene silencing effect of siRNA and inhibited tumor cell growth in vitro and in vivo, which may become a promising strategy for nucleic acid drug delivery in the future [189].

A more thorough understanding of the causes of different intracellular pathways is conducive to better rational and on-demand design of vectors, so as to meet more precise subcellular localization and achieve better drug efficacy. Although there is still a lack of strategies on changing intracellular transport pathway in the field of RNA delivery, it can be regarded as a good direction for future development, provided that a better correlation between the change of pathways and RNA effect is established.

Endosomal/lysosomal escape strategies and intracellular pathway alteration strategies have great application prospects in the design of RNA delivery vectors. This analysis is based on the following aspects. 1) Most vectors enter the cell through endocytosis. After being endocytosed into cells, the early endosome is the first to reach, which is a very important sorting compartment and determines the path of RNA vectors. Therefore, proper vector design can either directly increase the proportion of RNA escaping from endosomal/lysosomal pathway to cytoplasm, or make RNA bypass or less pass through endosomal/lysosomal pathway to the site of effect through non-lysosomal pathway. 2) A very important factor that restricts the efficacy of RNA drugs on the market and in clinical trials is the low endosomal/lysosomal escape efficiency—only less than 1% RNA can escape to cytoplasm. So even a very small increase in escape rate can be very helpful in enhancing RNA effect or lowering administration dosage.

3.7. Enhanced intracellular release of RNAs

The activity of RNA therapeutics relies on the efficient delivery of the RNAs to the cytosol of the cells at the target site, where it is translated into the active protein or exert gene editing/silencing effects. Meanwhile, released RNAs from nanocarriers in its stable and active form into cytosol is essential to fully accomplish the genomic therapy potential. So far, nanocarriers can achieve this release process either by introducing stimuli-sensitive chemical moieties that break the backbone of delivery system in response to endogenous stimuli (GSH, ROS, pH, enzymes) or through self-immolative charge alteration, which terminates the electrostatic attraction between the vector and RNAs.

In general, distinct characters between targeted tissue/cells and normal tissue/cells (e.g., cancer cells or tumor microenvironment vs normal tissue environment) act as a stimulus of the RNA release. Nanocarriers made for such a stimulus carry the RNAs in physiological environment while release RNAs when such nanocarriers enter in the distinct environment of the targeted cells and generate structural

### Table 8

| Types and mechanism of RNA release | Stimuli-sensitive chemical groups | Nanocarriers components | Release profile | Reference |
|-----------------------------------|----------------------------------|-------------------------|----------------|-----------|
| pH-responsive PIC micelles disassembly | Polyester | PEG$_{24}$-b-PCL$_{12}$ (COOH)$_{3-5}$, PLL, siRNA | The twice higher fluorescence intensity of released Alexa488-siRNA at pH 5.0 compared to pH 7.4 | [99] |
| Acid-responsive “shrinking”-degradation of shell | Diamine linker A | Chol-PAA, DODAP, DOPC, siRNA | At pH 5.5, −60% of the total amount of encapsulated dsDNA is released from the A-cross-linked PCLs in 12 h and near-quantitative release is observed within 48 h. Declined FRET effect between CdsQbxs and Cy3-siRNA with incubation time from 2–6 h. The spatial confocal microscopic images showed that green dots (FITC-siRNA) and red dots (RITC-CDS-SS-P) were observed separately after internalization | [190] |
| pH-sensitive separation of the shell and core of micelles | Hydrazone bond | eRGD-PEG-Hz-CS-HA2, octyl-Lys-9R, siRNA | Dated siRNA release upon treatment of the NPs with 10 mM DTT yielded siRNA migration identical to free siRNA | [191] |
| GSH-responsive degradation of polymer | Disulfide bond | Ad-PEG, β-CD-SS-PDMAEMA, siRNA | Complete siRNA release after incubated NPs with 5 mM glutathione for 15 min | [192] |
| GSH-responsive separation of hydrophilic and hydrophobic polymer | Disulfide linkages | mPEG-PCL-g-SS-PDMAEMA, siRNA | Micelleplexes treated with 10 mM DTT yielded siRNA migration identical to free siRNA | [193] |
| GSH-responsive degradation of polymer | Disulfide bonds | A single linear PBAE with a single linear PBAE with disulfide bonds along the polymer backbone, siRNA | Complete siRNA release after incubated NPs with 5 mM glutathione for 15 min | [194] |
| Hydrazide can react with the α-keto acid structure of anionic pyruvate to form α-oxohydrazone, resulting in the reduction of the cationic net charge of the cationic polymer | Hydrazide | PGlu(diethylenetriamine (DET)/hydrazide), siRNA | The siRNA release ratio was 25% when the pyruvate concentration was 3.0 mM | [195] |
| ROS-responsive hydrophobic to-hydrophilic shift and production of carboxyl groups to interfere with electrostatic interactions | Phenylboronic ester | Ang-PEG-b-PGlu, PEG-b-PGlu/Hb, siRNA | Efficient siRNA release upon treatment NPs with H$_2$O$_2$ at concentrations above 0.1 × 10$^{-3}$ M | [196] |
| ATP-responsive charge reversal | Borate ester bond | Chol-Dopa, PEI-FPBA, siRNA | The FRET ratio of Cy3- and Cy5-siRNA co-loaded polyplexes decreased sharply to about 20% with ATP treatment | [197] |
| Self-immolative degradation of oligo(carbonate-β-α-amino ester) into a neutral diketopiperazine through an ester-amide cyclization reaction | Oligo(carbonate-β-α-amino ester), mRNA | Oligo(carbonate-β-α-amino ester), mRNA | Self-immolative rearrangement (t$_{1/2}$ = 2 min) | [198] |
| Self-catalyzed hydrolysis of PDMAEA, which degrades from a polycation into polyanionic pAA in the presence of water releasing DMAE | PDMAEA | PDMAEA-PmPAA-PBA, siRNA | – | [199] |

Abbreviation: pAA: poly(acrylic acid), DMAE: dimethylaminoethanol, PEI-FPBA: 3-fluoro-4-carboxyphenylboronic acid-grafted PEI, PDMAEA-PmPAA-PBA: poly(dimethylaminoethyl) acrylate-P(N-(3-(1H-imidazol-1-yl)propyl)acrylamide-poly(butyl acrylate)).
change/destruction in response to the certain stimuli. The stimuli usually include intrinsic (redox potential, enzymes, cofactors, enzymatic products, and pH) or extrinsic stimuli (ultrasound, external magnetic field, temperature, and light). Examples of different nanocarriers used for RNAs release are listed in the Table 8.

3.7.1. Nanocarrier disassembling by electrostatic repulsion

Since most of nanocarriers encapsulated RNA by electrostatic interaction using cationic segments, undesired intracellular RNAs binding with cationic segments and insufficient RNAs release would hinder the effectiveness of RNA. Thus, stimuli-responsive charge reversal of cations from positive charge to negative charge was used to achieve RNAs release by electrostatic repulsion. In this strategy, Sun et al. [196] synthesized PEI-FPBA as the polycations binding with siRNA, and dopamine (with diol-containing moiety) conjugated with cholesterol as the hydrophobic part (Chol-Dopa). The ultimate micelles (PFCMDP) were assembled by the reaction between FPBA and Dopa via borate esters. Upon cell internalization, the intracellular negatively charged ATP could compete with Dopa to bind with FPBA, then effectively triggered the disassembly of micelles and reversed the charge of PEI-FPBA from positive to negative, forcing the release of siRNA by electrostatic repulsion (Fig. 12A).

Similarly, the combination of hydrophobic-hydrophilic transition and charge reversal of nanocarriers was also used for RNAs release. Shi et al. [195] used PEG-block-poly[N-(3-methacrylamidopropyl)guanidinium-co-4,4,4,4,5,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acrylate] (PEG-b-P(Gu/Hb)), Ang-PEG-block-poly(N-(3-methacrylamidopropyl) guanidinium) (Ang-PEG-b-PGu) and siRNA to construct a ROS-responsive nanomedicine. This “triple-interaction”-stabilized Ang-3i-NM@sRNA nanomedicine was based on the electrostatic and hydrogen bond interactions of the Gu’/PO3– bridge together with a hydrophobic interaction of phenylboronic ester. When encountered the reactive oxygen species enriched in cancer cells (ROS concentration in cancer cells up to 100 μM), the hydrophobic phenylboronic ester was converted to its hydrophilic counterpart with carboxyl groups. This hydrophobic-to-hydrophilic shift initially depleted the hydrophobic stabilization force and subsequently the newly produced carboxyl groups interfered with electrostatic and hydrogen bond interactions. This sequential “self-destruct” process enabled effective siRNA release (Fig. 12B).

3.7.2. Stimuli-responsive cleavage of nanocarrier backbone

In additional to electrostatic repulsion-based intracellular release of RNAs, introducing stimuli-sensitive chemical groups into the nanostructure to realize the cleavage of backbone and disassembly of nanocarriers in the specific intracellular environment is another strategy to facilitate rapid RNAs release.

Farokhzad et al. [199] developed a hypoxia-responsive NP (HRNP) by self-assembly of the hypoxia-responsive polypeptide, mPEG-block-poly(l-glutamide-graft-2-nitromidazole) (mPEG-b-(PLG-g-NI)), and cationic lipid-like compound (G0-C14) for delivery of CDC20 siRNA. Under the hypoxic tumor environment, conversion of the hydrophobic NI group to a hydrophilic 2-aminimidazole (AI) occurred as a result of a series of nitroreductases that catalyzed a single-electron reduction, leading to the disassembly of HRNP and a subsequent rapid release of cargo in tumor cells. Yan et al. [200] synthesized the furoxans-grafted PEI polymer (FDP) with caspase-3 responsive cleavable DEVD linker for siRNA delivery. After GSH-triggered NO release, and then increase the activity of caspase-3, the DEVD peptide sequence was cleaved to facilitate the disassembly of FDP/siRNA nanoplexes, thereby resulting in increased siRNAs of ~40% were released at 48 h and enhanced gene downregulation effects by ~2 fold compared with the caspase-3 non-responsive FDNP/siRNA nanoplexes.

Additionally, introducing the self-degradable moieties into the nanocarriers to achieve charge reversal via sequential self-immolative process have taken the above two strategies together, which may offer another route for RNA release. In this manner, not only the nanocarriers can achieve biodegradable, but also the RNAs can be effectively released. Waymouth et al. [197] reported a highly effective mRNA delivery system comprising charge-altering releasable transporters (CARTs). The oligo(carbonate-b-a-amino ester) was synthesized by facile organocatalytic ring-opening polymerization (OROP) and global deprotection, and then functionalized as polycations that non-covalently complexed, protected, and delivered polyamionic mRNA in the cytosol. As the pH was raised toward basic conditions, the oligo (a-amino ester) rapidly degraded in <5 min through intramolecular rearrangement of ester-to-amide isomerizations and controlled self-immolative degradation, during which cationic amines were converted to neutral amides. This charge alteration reduced or eliminated the electrostatic anion-binding ability of the originally cationic material, thereby facilitating decomplexation and release of anionic mRNA into the cytosol for translation.

Another common change is the self-catalyzed hydrolysis of PDMAEA (pKa ~ 7.1), which degrades from a polycation into negatively charged and non-toxic PAA in the presence of water releasing DMAE [201]. Moreover, the degradation time to form PAA is independent of pH (as tested between pH 5.5 and 10.1) and therefore the molecular weight of PDMAEA. Monteiro et al. [202] reported a polymer carrier consisted of a diblock copolymer with a first block of PDMAEA binding to siRNA. A second block consisting of PImPAA and PBA was designed to induce fusion with the endosome membrane that resulted in escape of the polymer/siRNA complex to the cytosol where release of the siRNA could occur after degradation to PAA (Fig. 13). The results showed the full release of siRNA from the nanocarriers at pH 7.6 after 17 h in water.

Overall, the stimuli-responsive RNAs platforms are highly desired for RNAs delivery and enhanced therapeutic effects of RNAs. It was worth noting that the response sensitivity of nanocarriers to above endogenous stimuli in specific disease states is an important factor for effective release of RNAs. The levels of these triggers can vary between cell lines/cell environments and even within the same tissue or organ, resulting in variable degrees of degradation. This can produce inconsistent results, especially when going from in vitro to in vivo experiments. Furthermore, after degradation, the materials should form biologically benign components avoiding toxic buildup in the tissues.

Currently, the complication arises in that the process of how RNAs are released from the nanocarriers in spatiotemporally programmable manners, including the detailed released kinetics, intracellular bioavailability and structural integrity of RNAs, are still unclear and lack of advanced evaluation methods.

3.8. The balance consideration for safety and efficacy of RNA delivery systems

Considering for clinical translation, the excipients or materials used for RNA formulation should be biocompatible and tolerable to ensure the safety of therapeutic RNA products and avoid excipient-induced immune activation. Additionally, the functional synthetic non-viral vectors that could protect RNA against degradation by ribonucleases, accumulate in specific tissue, facilitate cell internalization, and allow for the controlled release of the encapsulated therapeutic, were usually comprehensive nanosystems associated with unexpected adverse reaction. Therefore, the balance consideration for safety and efficacy of RNA delivery systems is to be necessary. The stable encapsulation and tissue/cell-specific targeting delivery systems would be beneficial to avoid biological effects of RNA drugs inducing unwanted toxicities in non-target tissues and cells. Meanwhile, efficient endosomal escape and controlled release of RNAs would also provide advantage for increasing the intracellular concentration of drugs, leading to reduction of concentration-dependent side effects such as off-target effects and immune stimulation.

The problems of positive charge-associated plasma protein aggregation, immune stimulation and nonspecific tissue accumulation are often concerned. In lipid-based RNA delivery, cationic lipids were...
Fig. 12. (A) ATP-Triggered Breakage of FPBA-Dopa and ATP-Activated Charge Reversal of PEI-FPBA [196]. Reproduced with the permission from Ref. 196. Copyright © 2018 American Chemical Society. (B) Schematic illustration of formation of Ang-3I-NM@siRNA stabilized by the three “triple-interaction” forces, namely, electrostatic, hydrogen bond, and hydrophobic interactions, and mechanisms of ROS triggered siRNA release. In the presence of tumoral ROS, the hydrophobic phenylboronic ester is converted to the hydrophilic counterpart bearing carboxyl groups. This process first reduces the hydrophobic stabilization force and subsequently interferes with the electrostatic and hydrogen bond interactions resulting in effective siRNA release [195]. Reproduced with the permission from Ref. 195. Copyright © 2019 John Wiley and Sons.
usually used an important materials for condensate RNA molecules in positive-charged nanovectors, which can interact with several proteins, lipoproteins, leading to the formation of the aggregates or premature release of the RNAs leading to the systematic toxicity [204]. In addition, cationic lipids can inhibit the protein kinase c activity and induce lung inflammations. They can also induce non-specific hepatic toxicity [205]. Moreover, PEG-lipid have reported to induce “accelerated blood clearance” phenomenon (ABC) attributed to the formation of PEG-specific antibodies and generate a potent IgM antibody response to PEG after repeated doses of PEGylated liposomes. For example, rare events of anaphylaxis have been reported after vaccination with mRNA-1273 and BNT162b2, with an incidence currently estimated at approximately 1 in 100,000. It has not been elucidated which component of the vaccine is responsible for allergic reactions, but there might be a possible role for the PEGylated lipid and a pre-existence of anti-PEG antibodies (IgEs and/or IgGs), as recently discussed in other reviews [206]. Meanwhile, polymer-based delivery systems also hold the drawback of undefined structural composition-associated potential toxicities, non-biocompatibility and non-biodegradability, and even unknown degradable fragments-induced metabolic toxicity in vivo.

Moreover, Nonspecific immune response to the therapeutic RNAs may initiate the unwanted side effects are also concerned. Although RNAs has specific intracellular target, unintended effects of the other genes having partial complementary regions can cause severe side effects ("off-target" effects). In addition to this, immune activation is another severe issue related to RNAs. Generally, free siRNAs in circulation could be recognized by toll-like receptors (TLRs), such as TLR3, TLR7, and TLR8 [207], to provoke innate immune responses or cytokine release syndrome, which are related to the dose, sequence, size, and folding of RNA agent. There is also growing interest in developing recombinant RNAs made and folded in living cells in vivo [208].

Up to now, several non-viral RNAs delivery systems were failed in clinical trials due to toxicity. The CALAA-01 (Calando Pharmaceuticals-01) is the first targeted, polymer-based NP-carrying siRNA to be systematically administered to humans for the treatment of solid tumors in 2008. CALAA-01 is a four-component system that is manufactured as a two-vial formulation for clinical dosing (Fig. 14). Vial 1 contains siRNA designed to reduce the expression of the M2 subunit of ribonucleotide reductase (RRM2). Vial 2 contains a mixture of three delivery components: (i) a linear, cationic cyclodextrin-based polymer (CDP), (ii) a hydrophilic polymer [adamantane PEG (AD-PEG)] used to promote NP stability in biological fluids, and (iii) a human transferrin protein (hTf)-targeting ligand (AD-PEG-hTf) displayed on the exterior of the NP to engage Tf receptors (hTfR) on the surface of the cancer cells. Vials 1 and 2 are mixed at the bedside, and the components self-assemble into ~75 nm NPs [209]. Although CALAA-01 formulations had a good pharmaceutical quality, it was terminated at phase Ib study due to the dose-limiting toxic events (DLTs) [210, 211]. Additionally, The SNALP is a first-generation LNP developed by Tekmira that is designed to deliver the siRNA to the targeted tissue by IV injection. The first drug (TKM-ApoB or PRO-040201) is an siRNA that targets the mRNA of ApoB and is designed to indirectly reduce the uptake of cholesterol in cells. A total of 17 patients received TKM-ApoB and one of the two that received the highest dosage of the drug exhibited flu-like symptoms that were consistent with siRNA induced immune stimulation. Although the drug did not show evidence of toxicity in the liver, the Phase I clinical study (NCT00927459) was terminated because patients exhibited only transient reductions in cholesterol levels [212].

Whereas the successful RNA-based therapies have been approved on the market, there are still certain challenges for systemic administration of RNA-based therapies using non-viral vectors. The challenges of stability are greater for mRNA-based therapy than for siRNA-based therapy, as the chemical modifications that confer stability on siRNA duplexes can often render mRNAs ineffective. The structure-activity/toxicity relationship of nanocarriers, especially the influence of each component within the NPs, as well as the in vivo spatiotemporal fate of
RNAs during the systematic delivery are also of great importance. Exploring the proper and advanced technologies for more detailed studies of toxicities in vivo may become the research focus.

Overall, to push forward RNAs from bench to clinic, improvement and balance in safety, delivery strategy, pharmacokinetics, and pharmacodynamics is required. Several hurdles mentioned above like endosomal escape, lower cellular uptake, rapid excretion, degradation by nucleases, and immune stimulation need to be overcome to achieve the maximum potential of the therapeutic RNAs. Combining all the solutions in one delivery system could lead to the development of the ideal nanocarrier, which, however, is a difficult task. Combining all the elements to get in one single vector would increase the complexity of the delivery system. Hence, it is indispensable to study the overall physiochemical aspects of each component, how they complement each other’s activity and, at the same time, perform their function independently. However, it is generally difficult for synthetic RNA delivery system to overcome all the hurdles despite the development of complicated structure with several functions. Nowadays, biomimetic delivery systems have attracted more and more interest on RNAs delivery, which exhibited improved balance of toxicity and efficacy.

4. Biomimetic vectors for RNAs delivery

The biomimetic vector is a new type of drug delivery system that has rapidly emerged in recent years. These biomimetic nanocarriers are usually constructed by taking advantage of endogenous substances, the function of the inherent protein, the endogenous processes, or certain biological structures. Endogenous substances include cells, biomembranes, proteins and organelles, etc.; endogenous processes have a wide range, such as exosomes-mediated signal transduction or substance transmission [214–217], T cell killing [218–221], antigen presentation [222,223], blood coagulation [224–226], virus invasion [227], etc. Naturally occurring structures refer to virus structures [228–231], exosome structures [232,233], cell structures [234–236], and so on. “Mimetic” refers to the imitation of “bio”, either by mimicking their basic functions by in vitro recombination to reproduce endogenous process or mode of action, or by using endogenous cells to achieve the direct production of drug-loading carriers, in order to make the drug delivery system obtain good targeting, low immunogenicity and other complex functional characteristics suitable for drug efficacy. Currently, different biomembrane originated from various types of cells, such as stem cells [237–239], human embryonic kidney (HEK)-293 cells [240,241], RBCs [242,243], platelet [244], endothelial cells [245], T cells [246] and cancer cells [247,248], have been developed as non-viral vectors for RNA delivery (Table 9) (Fig. 15). The emergence of the biomimetic drug delivery system can complement the advantages of synthetic carriers and realize functional integration to jointly solve the problems existing in each step of RNA delivery, which is a promising drug delivery system.

In designing of synthetic vectors, there is often a contradiction among giving the vector long circulation, low immunogenicity and high uptake properties simultaneously, while the composition is too complicated. For biomimetic vectors, they can fulfill the requirements at the same time due to the introduction of unmodified endogenous substances [239,247–249] or engineered biological components [242,250–252].

Firstly, the biomimetic carrier well inherits the natural multifunctional characteristics of endogenous substances, such as long circulation, biocompatibility and homologous targeting ability (Table 9 [239,248]). The long circulation and application safety in vivo of biomimetic carriers lie in the body’s self-recognition mechanism of endogenous substances. For example, CD47, a “don’t eat me” signaling molecule, is expressed on surface of all cells in the body [253,254]. Membrane-bound complement regulatory proteins such as CD55 can inhibit the activation of complement system [255]. In addition, the surface potential of endogenous protein and membrane is negative, and the negative surface charge can avoid the dilemma of coagulation, hemolysis and rapid clearance of cationic carriers during intravenous injection, achieving long circulation [256–259]. Therefore, the use of endogenous substances to camouflage nanocarriers can help them evade clearance by the immune system, prolong circulation time, and improve biocompatibility. The homologous targeting ability also relies on the inherent targeting properties of proteins on endogenous membranes [260–262].

Considering of long circulation, low immunogenicity and innate targeting ability of biomimetic vectors with inherent protein on their membrane, the easy programming/modification characteristics of cells or cell membranes can be exploited to construct engineered cells or cell membranes, endowing subsequently constructed biomimetic vectors with specific or enhanced targeting ability. Methods mainly involve: 1) plasmid introduction to construct fusion proteins in order to endue membrane components with targeting ability [263]; 2) avidin-biotin interaction [264]; 3) biorthogonal functionalization strategy [250,265–267]; 4) linking targeting peptides to lipid molecules to introduce exogenous ligands by membrane insertion [16,242]. All these methods, which endow carriers with targeting function by introducing endogenous substances, avoid the cumbersome chemical targeting modification and the potential influence of uncontrollable factors. It is beneficial to vectors’ construction and production and has a certain
### Table 9: Examples of biomimetic vectors for RNAs delivery.

| Biomimetic types | Endogenous components | RNA Type | RNA loading materials | The function of endogenous components | Reference |
|------------------|-----------------------|----------|-----------------------|----------------------------------------|-----------|
| Cell membrane    | Cell membrane of H1299 cells (a human NSCLC cell line) | siRNA    | PBAE                 | ① Homotypic targeting delivery ② Low immunogenicity for in vivo application ③ Long circulation ④ Improved immune escape ability | [262]     |
|                  | HeLa cell membranes   | siRNA    | PLGA                 | ① Increased tumor accumulation benefiting from the recognition and adhesion molecules on the surface of HeLa cells ② Protection of miRNA from degradation in body fluid ③ Avoidance of immune clearance ④ Targeting delivery to ischemic injured cardiomyocytes | [247]     |
|                  | MSCs membrane         | miRNA    | Mesoporous silica    | ① Excellent MSCs-mimicking tumor-targeting functionality | [239]     |
|                  | RGD decorated macrophage membrane (anchored by click chemistry) | siRNA    | Fe₃O₄ magnetic nanoclusters (PEI as a surfactant) | ① Prolonged circulations time ② Improved tumor accumulation ③ Increased tumor uptake ④ Targeting overexpressing αvβ3 integrin on the membrane surface of B16F10 cells | [250]     |
|                  | cRGD modified red blood cells (RBCs) membrane (lipid insertion) | siRNA    | Bovine serum albumin (BSA) | ① Longer circulation time and more tumor accumulation ② Immune escape ③ Protect siRNA from nonspecific clearance and immune responses ④ Biocompatibility ⑤ Prolonged blood circulation ⑥ High BBB transcytosis, effective tumor accumulation, and specific uptake by tumor cells in the brain owing to Angiopep-2's high affinity for both low-density lipoprotein receptors (LPRs) on the surface of endothelial cells in the BBB and overexpressed LPRs in GBM cells | [249]     |
|                  | Angiopep-2 peptide-modified RBCs membrane (lipid insertion) | siRNA    | PEI                  | ① High BBB transcytosis, effective tumor accumulation, and, specific uptake by tumor cells in the brain owing to Angiopep-2's high affinity for both low-density lipoprotein receptors (LPRs) on the surface of endothelial cells in the BBB | [288]     |
|                  | Platelet membrane     | siRNA    | Zeolitic imidazolate framework-8 (ZIF-8) metal-organic framework (MOF) | ① Tumor-targeting capability ② Biocompatibility ③ Protection of mRNA from nucleases in vivo ④ The ability to deliver mRNA and protein to endogenous host antigen presenting cells (Under the effect of externalization of the 'eat-me' signal of phosphatidylserine (PS) on the cell surface, the cell vaccine can be distributed to the liver and spleen) ⑤ Good biocompatibility and stability ⑥ Prolonged circulation | [284]     |
|                  | Whole blood cells      | mRNA     | Blood cells          | ① Neuron-specific targeting ability ② Long circulation ③ Low immunogenicity for in vivo application ④ The ability to cross the blood-brain barrier (BBB) ⑤ Targeting ability to breast cancer cells ⑥ Native tumor-homing capability of M1 EVs ⑦ The induction of repolarization of M2 macrophages to M1 macrophages ⑧ The ability to load mRNA ⑨ Targeting specificity of HER2+ cells | [251]     |
|                  | Rabies virus glycoprotein (RVG) modified exosomes from self-dervied dendritic cells (plasmid) | siRNA    | Exosomes             | ① Neuron-specific targeting ability ② Long circulation ③ Low immunogenicity for in vivo application | [263]     |
|                  | RVG modified exosomes derived from murine dendritic cells | siRNA    | Exosomes             | ① Neuron-specific targeting ability ② Long circulation ③ Low immunogenicity for in vivo application | [252]     |
|                  | AS1411 aptamer-modified EVs (cholesterol conjugation) | miRNA/siRNA | EVs              | ① Neuron-specific targeting ability ② Long circulation ③ Low immunogenicity for in vivo application ④ Targeting ability to breast cancer cells ⑤ Native tumor-homing capability of M1 EVs ⑥ The induction of repolarization of M2 macrophages to M1 macrophages | [285]     |
|                  | EVs from M1 macrophages | siRNA    | EVs                  | ① Neuron-specific targeting ability ② Long circulation ③ Low immunogenicity for in vivo application ④ Targeting specificity of HER2+ cells ⑤ The ability to load mRNA ⑥ Targeting specificity of HER2+ cells | [287]     |
|                  | Exosomes from human embryonic kidney (HEK) 293 cells modified with GE11 peptide or EGF (plasmid) | mRNA     | Exosomes             | ① Neuron-specific targeting ability ② Long circulation ③ Low immunogenicity for in vivo application ④ Targeting specificity of HER2+ cells ⑤ The ability to load mRNA ⑥ Targeting specificity of HER2+ cells | [241]     |
|                  | exosomes from HEK 293 cells anti-HER2 single-chain variable fragment modified EVs from HEK 293 cells | mRNA     | EVs                  | ① Neuron-specific targeting ability ② Long circulation ③ Low immunogenicity for in vivo application ④ Targeting specificity of HER2+ cells ⑤ The ability to load mRNA ⑥ Targeting specificity of HER2+ cells | [287]     |
|                  | EVs from HEK 293 T cells and human fibroblast | siRNA (integration in the pre-miR-451 backbone) | EVs              | ① Neuron-specific targeting ability ② Long circulation ③ Low immunogenicity for in vivo application ④ Targeting specificity of HER2+ cells ⑤ The ability to load mRNA ⑥ Targeting specificity of HER2+ cells | [287]     |
|                  | Tetrahedral DNA nanostructures (TDNs) modified EVs from HEK 293 T cells | gRNA     | EVs                  | ① Neuron-specific targeting ability ② Long circulation ③ Low immunogenicity for in vivo application ④ Targeting specificity of HER2+ cells ⑤ The ability to load mRNA ⑥ Targeting specificity of HER2+ cells | [287]     |
|                  | RVG modified exosomes from HEK 293 T cells (plasmid) | siRNA    | Exosomes             | ① Neuron-specific targeting ability ② Long circulation ③ Low immunogenicity for in vivo application ④ Targeting specificity of HER2+ cells ⑤ The ability to load mRNA ⑥ Targeting specificity of HER2+ cells | [287]     |
|                  | microvesicles from HEK 293 T cells | mRNA     | Microvesicles        | ① Neuron-specific targeting ability ② Long circulation ③ Low immunogenicity for in vivo application ④ Targeting specificity of HER2+ cells ⑤ The ability to load mRNA ⑥ Targeting specificity of HER2+ cells | [287]     |
|                  | Exosomes from HEK 293 T cells | mRNA     | Exosomes             | ① Neuron-specific targeting ability ② Long circulation ③ Low immunogenicity for in vivo application ④ Targeting specificity of HER2+ cells ⑤ The ability to load mRNA ⑥ Targeting specificity of HER2+ cells | [287]     |

(continued on next page)
constructed a targeted worm-like biomimetic gene vector and studied its application prospect. Recently, Xue’s group [16] designed and constructed a targeted worm-like biomimetic gene vector and studied its application in tumor therapy (Fig. 16A). The targeting modules, cRGD (targeting overexpressing αvβ3 integrin on the membrane surface of B16F10 cells), was introduced in RBCs membrane by lipid inserting of cRGD-PEG-DSPE spontaneously. The vector (RGD-RBC-RP) is obtained by wrapping the targeted erythrocyte membrane around a charge-reversible gene-protein core (worm-like), in which bovine serum

---

Table 9

| Biomimetic types | Endogenous components | RNA Type | RNA loading materials | The function of endogenous components | Reference |
|------------------|-----------------------|----------|-----------------------|---------------------------------------|-----------|
| EVs from HEK 293 T cells and MCF-7 cells | siRNA | EVs | The ability to deliver mRNA into inflamed macrophages in relatively high specificity | [292] |
| Exosomes derived from MSCs | miRNA | Exosomes | Selective homing of MSCs to the inflammatory site of injury | [293] |
| Exosomes from fibroblast-like mesenchymal cells | siRNA or shRNA | Exosomes | Low immunogenicity | [294] |
| EVs from MSCs | miRNA | EVs | CD47 on exosomes mediated protection from phagocytosis by circulating monocytes and macrophages | [295] |
| Exosomes from bone marrow MSCs | siRNA | Exosomes | Minimal cytotoxic effects | [296] |
| Exosomes from bone marrow MSCs exosomes derived from marrow stromal cells | siRNA | Exosomes | The capacity to home to the sites of metatstatic tumors when systemically administered in vivo | [297] |
| RVG modified exosomes from bone marrow MSC (plasmid) brain endothelial cell-derived exosomes | miRNA | Exosomes | A natural tropism for tumors and their metastases | [298] |
| EVs from primary endothelial cells bioengineered bacterial outer membrane vesicles (OMVs) (genetically fused ClyA with an HER2-specific affibody) exosomes originating from HeLa and ascites | siRNA | OMVs | Enhancement of blood circulating time | [299] |
| EVs from HS78Tds(i), mouse fibroblast L929 cell-derived microvesicles | siRNA | Microvesicles | Fine histocompatibility | [300] |
| microvesicles derived from human adult liver stem cells (HLSC) | miRNA mimics or miRNA inhibitors | Microvesicles | Delivery vehicles for anti-tumor miRNA therapy | [301] |
| Plasma exosomes | siRNA | Exosomes | The ability to cross the BBB | [302] |
| EVs from RBCs | ASO, sgRNA, mRNA | EVs | The ability to deliver miR-134 in vitro | [303] |
| Exosomes secreted from B16F0 melanoma cells | lncRNA | Exosomes | A carrier for siRNA delivery in vitro | [304] |
| EVs from endothelial progenitor cells | lncRNA | EVs | The ability to deliver miR-134 in vitro | [305] |
| EVs from HEK293 cells | lncRNA | EVs | Little toxicity | [306] |
| EVs from hepatocellular carcinoma Exosomes from oxaliplatin-resistant colorectal cancer cells and HEK 293 T cells Exosomes from synovial mesenchymal cells Exosomes from human malignant glioma cell lines U251 | circRNA | Exosomes | A protector for the inner siRNA | [307] |
| Plasma exosomes | siRNA | Exosomes | The ability to transfer therapeutic siRNA | [308] |
| EVs from MSCs | miRNA | EVs | The ability to deliver heterologous siRNAs to human blood mononuclear cells and lymphocytes in vitro | [309] |
| Plasma exosomes | siRNA | Exosomes | Safe (unlike EVs from nucleated cell types which pose potential risks for horizontal gene transfer and unlike plasma EVs that are heterogeneous with unpredictable contents) | [310] |
| EVs from MSCs | miRNA | EVs | Selective homing of MSCs to the inflammatory site | [311] |
| EVs from MSCs | miRNA | EVs | Protection of cargo and improvement of transfection efficiency | [312] |
| EVs from MSCs | miRNA | EVs | Protection of cargo and improvement of transfection efficiency | [313] |
| EVs from MSCs | miRNA | EVs | Protection of cargo and improvement of transfection efficiency | [314] |
albumin (BSA) is used to concentrate and protect siRNA. At the same time, pharmacokinetics and biological tissue distribution experiments were used to study the effect of worm-like nanoerythrocyte on circulation in vivo. The results indicated that RGD-RBC-RP had longer circulation time and more tumor accumulation. Intravenous injection of RGD-RBC-RP significantly knocked down survivin expression level and enhanced anti-tumor efficacy against B16F10 tumors. Therefore, modified erythrocyte membrane encapsulation is expected to achieve immune escape, long blood circulation and enhanced targeting capacity of gene carriers, thereby improving the bioavailability of siRNA.

In addition, the development of biomimetic drug delivery systems has also put forward insights into the loading methods of RNA. The new RNA loading modes brought by the development of biomimetic carriers are mainly active loading modes related to extracellular vesicles (EVs) (Fig. 15), which are naturally secreted nanoscale vesicles and used for intercellular communication or intracellular waste discharge [270–273]. EVs contains various types of RNA, including miRNA, IncRNA, mRNA, ribosomal RNA (rRNA) and circular RNA (circRNA), etc. [274,275], which are ideal RNA delivery carriers of natural origin. Up to now, EVs have been widely used as non-viral vectors for RNA delivery [276], including mRNA [8], siRNA [277,278], miRNA [279], sgRNA [280], ASO [281], etc. There are about 10^{14} EVs in the human body. Such a huge number of EVs can exist in body fluids and perform different functions in an orderly way, which must have particular modes of regulation. And, perhaps the answer to non-liver targeting is also hidden here. Therefore, how to better understand EVs as a natural signal or substance delivery carrier in the body, how to rationally modify the circulatory system of EVs naturally present in the body instead of treating them simply as ordinary lipid vesicles to exert drug-carrying capacity, and how to truly achieve “biomimetic” is the core point we need to think deeply about.

It is a well-known cell-mediated and active RNA self-packaging mode that cells express specific fusion proteins through plasmid or lentiviral transfection to give exosomes the ability to actively sort and encapsulate RNA [282]. This approach cleverly borrows the natural intracellular biosynthesis pathway of exosomes. Active RNA loading and release during exosome biogenesis is realized by the fusion of exosomal membrane proteins and different types of RNA binding proteins [274]. Li et al. [269] fused exosomal membrane protein CD9 with RNA-binding protein HuR (human antigen R) (Fig. 15C). HuR locating inside the vesicles could bind to miRNA or mRNA either natively harbors or is engineered with HuR recognition motif (AU rich element). The loading efficiency of RNAs of interest was improved in engineered exosomes and the enriched RNAs could be functional in the recipient cells. However, the release mechanism in target cells still needs to be further refined.

In 2021, Fu et al. [268] designed a novel approach to generate vectors containing therapeutic siRNA, moving the production site of
RNA delivery system from *in vitro* to *in vivo* (Fig. 16B). Plasmid DNA (pDNA) encoding an optimized siRNA expression part and a tissue-targeting tag fused to the N-terminus of Lamp2b was designed and synthesized *in vitro*. After intravenous injection of pDNA, host liver cells were reprogrammed by the genetic circuit. Driven by the promoter part, specific siRNA was transcribed and assembled into secreted exosomes anchored by guidance tags, which were delivered to desired tissues through blood circulation. Controllable RNA self-assembly and targeted delivery were induced in a dynamic environment *in vivo* and this therapeutic strategy was validated in three disease models. By transferring the model of *in vitro* cell factory to *in vivo* application and constructing *in vivo* cell factory to realize the “self-production and self-marketing” of RNA drug delivery system, it can not only avoid the tedious steps of large-scale extraction and purification of exosomes, but also reduce cost, which is beneficial to quality control and clinical translation. Currently, two exosomes-based RNA delivery vectors are in the clinical trials. The mesenchymal stromal cell-derived exosomes to deliver KrasG12D siRNA is in phase I clinical trial (NCT03608631), which is used for the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) with KrasG12D mutation [294]. Another biomimetic vectors-based RNA drug, allogenic mesenchymal stem cell-derived exosomes to deliver miR-124, is used for acute ischemic stroke and currently in phase I/II clinical trials (NCT03384433).
5. Summary and prospect

Since the RNA drugs have been successfully marketed, especially the mRNA vaccines, which have been approved most recently to combat against the unprecedented COVID-19 pandemic, a new era of RNAs has been opened up and witnessed. As RNAs provide a high degree of gene selectivity, which is difficult to achieve with the current treatment options, they hold massive potential to be used as a therapeutic tool for genetic disorders. With significant development in the nanocarriers and simultaneous advancement in the chemical modification, more and more RNA drugs translation from bench to bed will have good feasibility. Moreover, it can be believed that with the booming of RNA-based therapies, wider range of therapeutic targets and more diversity of diseases treatable from rare genetic disorders to common ones, such as infection and cancer, will be expanded in the future.

Although enormous improvement of non-viral vector has been achieved over the past few years, only a few RNA therapeutics have been successfully marketed. Part of the reason could be attributed to the numerous biological obstacles in delivery, difficulty of quality control, and the balance of the efficacy and safety of nanomedicine in vivo. Continuous effort is required to improve and develop a mature and sophisticated strategy for delivery system design. Especially strategies for the endosomal escape, cell and tissue targeting, and development of the novel biomaterials are crucial for the translation of RNAs from bench to bed. Moreover, the limitations of cost-effectiveness of RNAs, complexity of production, and standard of quality control are also vital. While great progress in the development of microfluidic systems and RNA synthesis procedures, providing scaling up feasibility, reproducibility and reduced immunogenicity for production of RNA nanocarriers, there is still a major technological gap limiting efficient in vivo transfection in specific cells. Besides, it is necessary to reduce the batch-to-batch variation of synthetic nanocarriers and build up quality evaluation standards for RNA delivery systems.

The advantages of biomimetic vectors provide new insights into the delivery mode of RNA in vivo. Compared with the complexity of the synthesis non-viral vectors with integration of multi-functional modules, biomimetic carriers can obtain composite functional characteristics through introduction of a single endogenous module. The biomimetic carrier not only has excellent circulation and biocompatibility, but also is easy to obtain different targeting properties through innate acquisition or acquired modification. However, there is no biomimetic vectors-based RNA drug approved in the market currently. The reasons why the biomimetic vectors has not yet achieved clinical translation mainly include batch-to-batch variation, difficulties of large scale production and immunogenicity and side effects of long-term application due to the complexity of heterologous components [283]. The solution of these problems and the expansion of available exogenous biomaterials will promote the further development of biomimetic carriers and RNAs delivery; so that the valuable biomimetic carriers will be truly benefit clinical patients.

Declaration of Competing Interest

The authors stated that they have no competing interests.

Acknowledgments

The authors acknowledge financial support from the projects of National Natural Science Foundation of China (Grant No. 81773650, 81690264 and 81973259), Beijing Natural Science Foundation (No. J200018), National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology of China (Grant No. 2018ZX09J21003-004).

References

[1] X.M. Anguela, K.A. High, Entering the modern era of gene therapy, Annu. Rev. Med. 70 (2019) 273–288.
[2] Y.H. Jeon, Y.T. Jung, Production of a replicating retroviral vector expressing Reovirus fast protein for cancer gene therapy, J. Virol. Methods 299 (2022) 143322.
[3] M.H. Miname, V.Z. Rocha, R.D. Santos, The role of RNA-targeted therapeutics to reduce ASCVD risk: what have we learned recently? Curr. Atheroscler. Rep. 23 (8) (2021) 40.
[4] https://www.fda.gov/news-events/press-announcements/fda-gradents-autoload-ed-approval-first-targeted-treatment-rose-chueme-muscular-dystrophy-mutat-
[5] J.A. Kulkarni, D. Witzigmann, S.B. Thomson, S. Chen, B.R. Leavitt, P.R. Cullis, r van der Meer, Author correction: the current landscape of nucleic acid therapeutics, Nat. Nanotechnol. 7 (7) (2012) 456.
[6] J. Bai, Y. Zhang, S. Yin, G. Yang, Y. Wang, Therapeutic effects of simultaneous delivery of nerve growth factor mRNA and protein via exosomes on cerebral ischemia, Molecular Therapy. Nucleic Acids 21 (2022) 510–522.
[7] Z. Yang, J. Shi, J. Xie, Y. Wang, J. San, T. Liu, Y. Zhao, X. Zhao, X. Wang, Y. Ma, M. Valko, C. Chiang, W. Deng, Y. Chen, Y. Fu, K.J. Kwak, Y. Fan, C. Kang, C. Yin, J. Rhee, P. Bertani, J. Otero, W. Lu, K. Yun, A.S. Lee, W. Jiang, L. Teng, B.Y. S. Kim, L.J. Lee, Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation, Nature Biomed. Eng. 4 (1) (2020) 69–83.
[8] E.J. Haas, F.J. Angelo, J.M. McLaughlin, E. Anis, S.R. Singer, F. Khan, N. Brooks, M. Smaja, G. Mircus, K. Pan, J. Southern, D.L. Swerdlow, L. Jodar, Y. Levy, S. Alroy-Preis, Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data, The Lancet 397 (105287) (2021) 1819–1829.
[9] L. Martinez-Bax, C. Trojano-Samarrais, A. Miqueluz, M. Guvera, M. Fernandez-Huerta, C. Burgui, I. Casado, M.E. Portillo, A. Navascues, C. Ezpeleta, J. Castilla, W.G.S.C. Navare, Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navare, Spain, April to August 2021, Eurosurveillance 26 (39) (2021) 2109894.
[10] N. Dammes, M. Goldsmith, S. Ramisetti, J.J.L. Dearing, N. Veiga, A.B. Packard, D. Peer, Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics, Nat. Nanotechnol. 16 (9) (2021) 1030–1038.
[11] R. Li, Ball, K.A. Haji, J. Virzelm, P. Bajaj, K.A. Whitehead, Lipid nanoparticle formulations for enhanced co-delivery of siRNA and mRNA, Nano Lett. 18 (6) (2018) 3814–3822.
[12] G.J. Chen, J.C. Wang, E.Y. Zhao, L.Y. Gao, Q. Feng, X.Y. Liu, Z.X. Zhao, X.F. Ma, W.J. Hou, L.B. Zhang, W.L. Lu, Q. Zhang, Self-assembly cationic nanoparticles based on cholesterol-grafted bioreducible poly(amidoamine) for siRNA delivery, Biomaterials 34 (21) (2013) 5303–5316.
[13] D. Luong, P. Kesharwani, R. Deshmukh, M.C.I. Mohd Amin, U. Gupta, K. Greish, A. K. Iyer, PEGylated PAMAM dendrimers: enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery, Acta Biomater. 43 (2016) 14–29.
[14] T. Zimmerman, V. Karsten, A. Chan, J. Chiesa, M. Boyce, B.R. Bettencourt, R. Hataburat, S. Nochur, A. Vaishnavn, J. Gollob, Clinical proof of concept for a novel hepatocyte-targeting GaNac-siRNA conjugate, Mol. Ther. 25 (1) (2017) 71–78.
[15] Y. Wang, X. Ji, M. Ruan, W. Liu, R. Song, J. Dai, W. Xue, Worm-like biomimetic nanoribbons carrying siRNA for melanoma gene therapy, Small 14 (7) (2018), e1803002.
[16] N. Dammes, M. Goldsmith, S. Ramisetti, J.J.L. Dearing, N. Veiga, A.B. Packard, D. Peer, Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics, Nat. Nanotechnol. 16 (9) (2021) 1030–1038.
[17] B. Kim, J.H. Park, M.J. Sailor, Rekindling RNAi therapy: materials design requirements for in vivo siRNA delivery, Adv. Mater. 31 (49) (2019) e1903637.
[18] S. Yonezawa, H. Koide, T. Anai, Recent advances in siRNA delivery mediated by lipid-based nanoparticles, Adv. Drug Deliv. Rev. 154 (2020) 64–78.
[19] Y.Z. Dong, D.J. Siegwart, D.G. Anderson, Strategies, design, and chemistry in siRNA delivery systems, Adv. Drug Deliv. Rev. 144 (2019) 133–147.
[20] Komirin approved for CMV reinitis: first antiepileptic drug, AIDS Treat News 302 (1998) 7.
[21] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro
[22] G. Markov, A. Oshchepkova, N. Mironova, Immunotherapy based on dendritic cell-targeted/-derived extracellular vesicles-a novel strategy for enhancement of the anti-tumor immune response, Front. Pharmacol. 10 (2019) 1152.
[23] E.J. Haas, F.J. Angelo, J.M. McLaughlin, E. Anis, S.B. Singer, F. Khan, N. Brooks, M. Smaja, G. Mircus, K. Pan, J. Southern, D.L. Swerdlow, L. Jodar, Y. Levy, S. Alroy-Preis, Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data, The Lancet 397 (10527) (2021) 1819–1829.
[24] A. Khurana, P. Allawadhi, I. Khurana, R. Weiskirchen, A.K. Banothu, D. Chhabra, K. Joshi, K.K. Bharani, Role of nanotechnology behind the success of mRNA vaccines for COVID-19, Nano Today 38 (2021) 101142.
Y. Yan et al.  Journal of Controlled Release 342 (2022) 241–279

[26] H. Huang, C.L. Zhang, S.P. Yang, W. Xiao, Q. Zhang, X.R. Song, The investigation of siRNA vaccines formulated in liposomes administered in multiple routes against SARS-CoV-2, Cell Discov. 5 (3) (2019) 167–177.

[27] I. Ermilova, J. Swenson, DOPC versus DOPE as a helper lipid for gene-therapies: molecular dynamics simulations with DLin-MC3-DMA, Phys. Chem. Chem. Phys. 22 (48) (2020) 28256–28268.

[28] B.L. Mui, Y.K. Tam, M. Jayaraman, S.M. Ansell, X.Y. Du, Y.Y.C. Tam, P.J.C. Lin, S. Chen, J.K. Narayananurag, K.G. Rajvej, M. Manoharan, A. Akinc, M.A. Maier, P. Cullis, T.D. Madden, M.J. Hope, Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA Lipid nanoparticles, Mol. Ther. Nucleic Acids 2 (2013) e139.

[29] X.P. Zhang, V. Goel, G.J. Robbie, Pharmacokinetics of patisarin, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis (ATTR amyloidosis), J. Clin. Pharmacol. 60 (1) (2020) 37–49.

[30] A.D. Springer, S.F. Dowdy, GalNAc-siRNA conjugates: leading the way for delivery of RNAi to the liver, Nat. Rev. Mol. Cell Biol. 19 (4) (2018) 255–260.

[31] Y. Yamada, S. Tato, S. Nakamura, H. Harashima, Evaluation of drug delivery system from viewpoint of controlled intracellular trafficking and selective tissue targeting toward future nanomedicine, J. Control. Release 327 (2020) 533–545.

[32] S.F. Dowdy, Overcoming cellular barriers for RNA therapeutics, Nat. Biotechnol. 35 (3) (2017) 222–229.

[33] C.R. Brown, S. Gupta, T. Racic, G. He, S. Lentinii, R. Malone, M. Yu, S. Matsuda, S. Shulga-Morska, A.V. Nair, C.S. Theille, K. Schmidt, A. Shahraz, V. Goel, G.R. Parmar, R. Schierle, M.K. Schlerph, M. Jayaraman, M. Manoharan, D.B. Maier, V. Jadhav, Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates, Nuclear Acids Res. 48 (21) (2020) 11882–11884.

[34] J. Soutschek, A. Akinc, A. Iwamoto, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, C.R. Brown, S. Gupta, J. Qin, T. Racie, G. He, S. Lentini, R. Malone, M. Yu, S.F. Dowdy, Overcoming cellular barriers for RNA therapeutics, Nat. Biotechnol. 35 (3) (2017) 222–229.

[35] C.R. Brown, S. Gupta, T. Racic, G. He, S. Lentinii, R. Malone, M. Yu, S. Matsuda, S. Shulga-Morska, A.V. Nair, C.S. Theille, K. Schmidt, A. Shahraz, V. Goel, G.R. Parmar, R. Schierle, M.K. Schlerph, M. Jayaraman, M. Manoharan, D.B. Maier, V. Jadhav, Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates, Nuclear Acids Res. 48 (21) (2020) 11882–11884.

[36] J. Soutschek, A. Akinc, A. Iwamoto, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, C.R. Brown, S. Gupta, J. Qin, T. Racie, G. He, S. Lentini, R. Malone, M. Yu, S.F. Dowdy, Overcoming cellular barriers for RNA therapeutics, Nat. Biotechnol. 35 (3) (2017) 222–229.

[37] C.R. Brown, S. Gupta, T. Racic, G. He, S. Lentinii, R. Malone, M. Yu, S. Matsuda, S. Shulga-Morska, A.V. Nair, C.S. Theille, K. Schmidt, A. Shahraz, V. Goel, G.R. Parmar, R. Schierle, M.K. Schlerph, M. Jayaraman, M. Manoharan, D.B. Maier, V. Jadhav, Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates, Nuclear Acids Res. 48 (21) (2020) 11882–11884.

[38] J. Soutschek, A. Akinc, A. Iwamoto, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Lentinii, R. Malone, M. Yu, S. Matsuda, S. Shulga-Morska, A.V. Nair, C.S. Theille, K. Schmidt, A. Shahraz, V. Goel, G.R. Parmar, R. Schierle, M.K. Schlerph, M. Jayaraman, M. Manoharan, D.B. Maier, V. Jadhav, Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates, Nuclear Acids Res. 48 (21) (2020) 11882–11884.

[39] J. Soutschek, A. Akinc, A. Iwamoto, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Lentinii, R. Malone, M. Yu, S. Matsuda, S. Shulga-Morska, A.V. Nair, C.S. Theille, K. Schmidt, A. Shahraz, V. Goel, G.R. Parmar, R. Schierle, M.K. Schlerph, M. Jayaraman, M. Manoharan, D.B. Maier, V. Jadhav, Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates, Nuclear Acids Res. 48 (21) (2020) 11882–11884.

[40] J. Soutschek, A. Akinc, A. Iwamoto, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Lentinii, R. Malone, M. Yu, S. Matsuda, S. Shulga-Morska, A.V. Nair, C.S. Theille, K. Schmidt, A. Shahraz, V. Goel, G.R. Parmar, R. Schierle, M.K. Schlerph, M. Jayaraman, M. Manoharan, D.B. Maier, V. Jadhav, Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates, Nuclear Acids Res. 48 (21) (2020) 11882–11884.

[41] J. Soutschek, A. Akinc, A. Iwamoto, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Lentinii, R. Malone, M. Yu, S. Matsuda, S. Shulga-Morska, A.V. Nair, C.S. Theille, K. Schmidt, A. Shahraz, V. Goel, G.R. Parmar, R. Schierle, M.K. Schlerph, M. Jayaraman, M. Manoharan, D.B. Maier, V. Jadhav, Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates, Nuclear Acids Res. 48 (21) (2020) 11882–11884.

[42] J. Soutschek, A. Akinc, A. Iwamoto, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Lentinii, R. Malone, M. Yu, S. Matsuda, S. Shulga-Morska, A.V. Nair, C.S. Theille, K. Schmidt, A. Shahraz, V. Goel, G.R. Parmar, R. Schierle, M.K. Schlerph, M. Jayaraman, M. Manoharan, D.B. Maier, V. Jadhav, Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates, Nuclear Acids Res. 48 (21) (2020) 11882–11884.

[43] J. Soutschek, A. Akinc, A. Iwamoto, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Lentinii, R. Malone, M. Yu, S. Matsuda, S. Shulga-Morska, A.V. Nair, C.S. Theille, K. Schmidt, A. Shahraz, V. Goel, G.R. Parmar, R. Schierle, M.K. Schlerph, M. Jayaraman, M. Manoharan, D.B. Maier, V. Jadhav, Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates, Nuclear Acids Res. 48 (21) (2020) 11882–11884.
[118] K. Knop, R. Hoogenboom, D. Fischer, U.S. Schubert, Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives, Angew. Chem. Int. Ed. 49 (36) (2010) 7058–7060.
[119] K.P. Garcia, K. Zanchini, L. Barbaro, J.A. Barreto, W. O. Fischer, U.S. Schubert, Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives, Angew. Chem. Int. Ed. 49 (36) (2010) 7058–7060.
[120] M.A. Jackson, L. Barbaro, J. Zanchini, L. Barbaro, J.A. Barreto, W. O. Fischer, U.S. Schubert, Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives, Angew. Chem. Int. Ed. 49 (36) (2010) 7058–7060.
[121] T. Zhang, Y. Huang, X. Ma, N. Gong, X. Liu, L. Ye, B. Hu, C. Li, J.H. Tian, A. Magrini, J. Zhang, W. Guo, J.F. Xing, M. Botini, J.X. Liang, Fluorinated oligomeric nanorubbers for highly efficient silica-mediated gene silencing in serum-containing media by effective endosomal escape, Nano Lett. 18 (10) (2018) 6301–6311.
[122] C. Fang, B. Shi, Y.Y. Pei, M.H. Hong, J. Wu, H.Z. Chen, In vivo tumor targeting of tumor necrosis factor-alpha loaded stealth nanoparticles: effect of MOPEG molecular weight and particle size, Eur. J. Pharm. Sci. 27 (1) (2006) 23–37.
[123] C.D. Walkley, J.B. Olsen, H.B. Guo, A. Emili, W.C.W. Chan, Nanoparticle size and shape-dependent tumor targeting in vivo, J. Am. Chem. Soc. 134 (4) (2012) 2129–2147.
[124] J.W. Yoo, E. Chambers, S. Mitragotri, Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects,Curr. Pharm. Des. 16 (21) (2010) 2298–2307.
[125] Y.L. Zhang, Z.G. Teng, Q.O. Ni, L. Tan, X.F. Cao, Y.T. Wen, L.Q. Wu, C. Fang, B. Xan, W.W. Zhang, G.M. Lu, Ordinarily curled silica nanoparticles with a small size and macromolecular loading pores: synthesis and delivery of macromolecules to eradicate drug-resistant cancer, ACS Appl. Mater. Interfaces 12 (52) (2020) 757810–757820.
[126] X. Jiang, W. Qu, D. Pan, Y. Ren, J.M. Williford, H.G. Cui, E. Luijten, H.Q. Mao, Plasmid-templated shape control of condensed DNA-block copolymer nanoparticles, Adv. Mater. 25 (2) (2013) 227–232.
[127] D.L. Janssen, H. Li, P. Guo, The effect of particle size and shape of nanoparticles on biodistribution, Mol. Ther. 26 (3) (2018) 784–792.
[128] A.C. Anselmo, M. Zhang, S. Kumar, D.R. Vogus, S. Menegatti, M.E. Helgeson, S. Mitragotri, Elasticity of nanoparticles influences their blood circulation, Plasmid-templated shape control of condensed DNA-block copolymer nanoparticles, Bioconjugate Chem. 23 (9) (2012) 2542–2548.
[129] M.J. Ernsting, M. Murakami, A. Roy, S.D. Li, Factors controlling the molecular age, Nat. Rev. Immunol. 11 (11) (2011) 788–794.
[130] K.P. Garcia, K. Zanchini, L. Barbaro, J.A. Barreto, W. O. Fischer, U.S. Schubert, Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives, Angew. Chem. Int. Ed. 49 (36) (2010) 7058–7060.
[131] H.S. Min, H.L. Kim, M. Naito, A. Ogura, T. Koh, K. Hayashi, B.S. Kim, S. Fukushima, Y. Anzaku, K. Miya, K. Kataoka, Systemic delivery of antisense oligonucleotides across the blood-brain barrier with a glucose-coated polymeric nanoparticle, Angew. Chem. Int. Ed. 59 (21) (2020) 8173–8180.
[132] Q. Cheng, T. Wei, L. Farbalk, I.T. Johnson, S.A. Dillard, D.J. Siegwart, Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing, Nano Lett. 15 (4) (2020) 313–320, s.
[133] K. Knop, R. Hoogenboom, D. Fischer, U.S. Schubert, Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives, Angew. Chem. Int. Ed. 49 (36) (2010) 7058–7060.
[134] S.G. Jadav, S.F. Dowdy, Overcoming delivery barriers with LNPs, Nat. Mater. 20 (5) (2021) 575–577.
[135] L. Wayteck, H. Dewitte, L. De Backer, K. Breckpot, J. Demester, S.C. De Smedt, K. Raemdonck, Hitchhiking nanoparticles: reversible coupling of lipid-based nanoparticles to cytotoxic T lymphocytes, Biomaterials 77 (2016) 243–254.
[136] N. Meng, D. Grimm, Membrane-destabilizing ionic phospholipids: Novel components for organ-targeted mRNA or siRNA delivery and CRISPR-Cas gene editing, Signal Transduc. Tar. 6 (1) (2021) 206.
[137] T. Zhang, Y. Wang, X.F. Zhao, J.L. Zhang, H.Y. Hu, M.X. Qiao, X.L. Zhao, D. Feng, K.商务, J. Yang, S. Duan, Y. Liu, F. Meng, L. Yin, Fluorinated alpha-helical polypeptides synchronize mucus permeation and cell penetration toward highly efficient pulmonary siRNA delivery against acute lung injury, Nano Lett. 20 (3) (2020) 1738–1746.
[138] A. Kohata, P.K. Hashim, K. Okuro, T. Aida, Transferrin-appended nanocaplet for tumor targeting, Adv. Mater. 21 (2) (2013) A309–A312.
[139] C. Ge, J. Yang, S. Duan, Y. Liu, F. Meng, L. Yin, Fluorinated alpha-helical polypeptides synchronize mucus permeation and cell penetration toward highly efficient pulmonary siRNA delivery against acute lung injury, Nano Lett. 20 (3) (2020) 1738–1746.
[140] Y.H. Cheng, C.L. He, J.E. Riviere, N.A. Monteiro-Riviere, Z.M. Lin, Meta-analysis of nanoparticle delivery to tumors using a physiologically based pharmacokinetic model and simulation approach, ACS Nano 14 (5) (2020) 3075–3095.
[141] T.Y. Jiang, N. Ting, L. Xue, Y. Guo, L. Guo, H. Long, Y. Zhou, S. Duan, Y. Liu, D. Feng, K.商务, J. Yang, S. Duan, Y. Liu, F. Meng, L. Yin, Fluorinated alpha-helical polypeptides synchronize mucus permeation and cell penetration toward highly efficient pulmonary siRNA delivery against acute lung injury, Nano Lett. 20 (3) (2020) 1738–1746.
[142] J.J. Li, Z.S. Ge, S.Y. Liu, PEG-sheddable polypeptide micelles as smart gene carriers based on MMP-cleavable peptide-linked block copolymers, Chem. Commun. 49 (62) (2013) 6974–6976.
[143] T. Zhang, Y. Wang, X.F. Zhao, J.L. Zhang, H.Y. Hu, M.X. Qiao, X.L. Zhao, D. Feng, K.商务, J. Yang, S. Duan, Y. Liu, F. Meng, L. Yin, Fluorinated alpha-helical polypeptides synchronize mucus permeation and cell penetration toward highly efficient pulmonary siRNA delivery against acute lung injury, Nano Lett. 20 (3) (2020) 1738–1746.
Methods of isolating extracellular vesicles impact downstream analyses of their cargoes, Methods 87 (2015) 3–10.

K.L. Phan, D. Boczkowski, J. Dannull, S.T. Lee, W. Im, J.J. Ban, M. Lee, K.H. Jung, S.K. Lee, K. Chu, M. Kim, Exosome-mediated delivery of small RNAs into extracellular vesicles by sonication, Cell. Mol. Bioeng. 11 (20) (2021) 9988–10000.

T. Trung, C. Campbell, W. Little, D.G. Anderson, D. Gibbings, Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for targeted exosome-mediated delivery of miR-124 promotes neurogenesis after ischemia, Mol. Ther. Nucleic Acids 7 (2017) 278–287.

T.Z. Yang, B. Fogarty, B. LaForge, S. Aziz, T. Pham, L.N. Lai, S.H. Bai, Delivery of TGF-β1 interfering RNA to vascular endothelial growth factor in zebrafish using natural RNAi technology to secrete exosome nanovesicles for the treatment of breast cancer, ACS Nano 8 (2014) 1525–1537.

J.L. Yang, X.F. Zhang, X.J. Chen, L. Yang, G.D. Yang, Exosome mediated delivery of miR-124 reduces tumor growth in mice, Biomaterials 35 (14) (2014) 4390–4400.

V. Gujrati, S. Kim, S.H. Kim, J.J. Min, H.E. Choy, S.C. Kim, S. Jon, Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy, ACS Nano 8 (2014) 1525–1537.

J.L. Yang, X.F. Zhang, X.J. Chen, L. Yang, G.D. Yang, Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia, Mol. Ther. Nucleic Acids 7 (2017) 278–287.

T.Z. Yang, B. Fogarty, B. LaForge, S. Aziz, T. Pham, L.N. Lai, S.H. Bai, Delivery of TGF-β1 interfering RNA to vascular endothelial growth factor in zebrafish using natural RNAi technology to secrete exosome nanovesicles for the treatment of breast cancer, ACS Nano 8 (2014) 1525–1537.

V. Gujrati, S. Kim, S.H. Kim, J.J. Min, H.E. Choy, S.C. Kim, S. Jon, Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy, ACS Nano 8 (2014) 1525–1537.

J.L. Yang, X.F. Zhang, X.J. Chen, L. Yang, G.D. Yang, Exosome mediated delivery of miR-124 reduces tumor growth in mice, Biomaterials 35 (14) (2014) 4390–4400.

V. Fonsato, F. Collino, M.B. Herrera, C. Cavallari, M.C. Deregibus, B. Cisterna, S. Bruno, R. Romagnoli, M. Sulzigner, C. Yeta, G. Camussi, Human liver stem cell-derived microvesicles inhibit hepatic growth in SCID mice by delivering antitumor miRNA, Stem Cells 30 (9) (2012) 1985–1998.

J. Wahlgren, T.D. Karlsson, M. Brisslert, F. Vaziri Sani, E. Telemo, P. Sunnerhagen, Y. Yan et al. pancreatic cancer, Nature 546 (7659) (2017) 498–503.

R. Kalluri, Exosomes facilitate therapeutic targeting of oncogenic KRAS in non-small cell lung cancer, J. Extracell Vesicles 6 (2017) 1–10.

R. Pavlovicz, A.C.P. Azevedo-Pouly, J. Chalmers, C.L. Li, M.A. Phelps, T. O’Hern, L.M. Metelko, J.L. Wilkinson-Berka, A.F. Wise, S.D. Ricardo, Mesenchymal stem cells deliver therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a microRNA backbone, Nat. Biotech. 30 (52) (2020) 2006515.

F. Zhang, Y.J. Zhang, J. Li, C.Y. Zhang, Targeted exosome-mediated delivery of therapeutic dose of silencing RNA to inhibit vascular endothelial growth factor in zebrafish using natural RNAi technology to secrete exosome nanovesicles for the treatment of breast cancer, ACS Nano 8 (2014) 1525–1537.

J.L. Yang, X.F. Zhang, X.J. Chen, L. Yang, G.D. Yang, Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia, Mol. Ther. Nucleic Acids 7 (2017) 278–287.

T.Z. Yang, B. Fogarty, B. LaForge, S. Aziz, T. Pham, L.N. Lai, S.H. Bai, Delivery of TGF-β1 interfering RNA to vascular endothelial growth factor in zebrafish using natural RNAi technology to secrete exosome nanovesicles for the treatment of breast cancer, ACS Nano 8 (2014) 1525–1537.

V. Gujrati, S. Kim, S.H. Kim, J.J. Min, H.E. Choy, S.C. Kim, S. Jon, Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy, ACS Nano 8 (2014) 1525–1537.

J.L. Yang, X.F. Zhang, X.J. Chen, L. Yang, G.D. Yang, Exosome mediated delivery of miR-124 reduces tumor growth in mice, Biomaterials 35 (14) (2014) 4390–4400.

V. Fonsato, F. Collino, M.B. Herrera, C. Cavallari, M.C. Deregibus, B. Cisterna, S. Bruno, R. Romagnoli, M. Sulzigner, C. Yeta, G. Camussi, Human liver stem cell-derived microvesicles inhibit hepatic growth in SCID mice by delivering antitumor miRNA, Stem Cells 30 (9) (2012) 1985–1998.

J. Wahlgren, T.D. Karlsson, M. Brisslert, F. Vaziri Sani, E. Telemo, P. Sunnerhagen, Y. Yan et al. pancreatic cancer, Nature 546 (7659) (2017) 498–503.

R. Kalluri, Exosomes facilitate therapeutic targeting of oncogenic KRAS in non-small cell lung cancer, J. Extracell Vesicles 6 (2017) 1–10.

R. Pavlovicz, A.C.P. Azevedo-Pouly, J. Chalmers, C.L. Li, M.A. Phelps, T. O’Hern, L.M. Metelko, J.L. Wilkinson-Berka, A.F. Wise, S.D. Ricardo, Mesenchymal stem cells deliver therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a microRNA backbone, Nat. Biotech. 30 (52) (2020) 2006515.

F. Zhang, Y.J. Zhang, J. Li, C.Y. Zhang, Targeted exosome-mediated delivery of therapeutic dose of silencing RNA to inhibit vascular endothelial growth factor in zebrafish using natural RNAi technology to secrete exosome nanovesicles for the treatment of breast cancer, ACS Nano 8 (2014) 1525–1537.

J.L. Yang, X.F. Zhang, X.J. Chen, L. Yang, G.D. Yang, Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia, Mol. Ther. Nucleic Acids 7 (2017) 278–287.

T.Z. Yang, B. Fogarty, B. LaForge, S. Aziz, T. Pham, L.N. Lai, S.H. Bai, Delivery of TGF-β1 interfering RNA to vascular endothelial growth factor in zebrafish using natural RNAi technology to secrete exosome nanovesicles for the treatment of breast cancer, ACS Nano 8 (2014) 1525–1537.

V. Gujrati, S. Kim, S.H. Kim, J.J. Min, H.E. Choy, S.C. Kim, S. Jon, Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy, ACS Nano 8 (2014) 1525–1537.

J.L. Yang, X.F. Zhang, X.J. Chen, L. Yang, G.D. Yang, Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia, Mol. Ther. Nucleic Acids 7 (2017) 278–287.

T.Z. Yang, B. Fogarty, B. LaForge, S. Aziz, T. Pham, L.N. Lai, S.H. Bai, Delivery of TGF-β1 interfering RNA to vascular endothelial growth factor in zebrafish using natural RNAi technology to secrete exosome nanovesicles for the treatment of breast cancer, ACS Nano 8 (2014) 1525–1537.

V. Gujrati, S. Kim, S.H. Kim, J.J. Min, H.E. Choy, S.C. Kim, S. Jon, Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy, ACS Nano 8 (2014) 1525–1537.

J.L. Yang, X.F. Zhang, X.J. Chen, L. Yang, G.D. Yang, Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia, Mol. Ther. Nucleic Acids 7 (2017) 278–287.